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Gene-fusions are a prevalent class of genetic variants that have been implicated in 
the onset and progression of variety of cancer types (Mitelman et al. 2007). Gene-fusions 
often lead to oncogenic activation by creating fusion-protein or resulting in 
transcriptional deregulation of cancer genes (Rabbitts 1994; Tomlins et al. 2005).  
Recurrent gene-fusions, in particular, considered as ‘driving’ or causal mutations that 
have often been employed as cancer biomarkers (Mitelman 2000; Laxman et al. 
2008)and, in some cases as, potential therapeutic targets (Baselga et al. 1996; Druker et 
al. 2001). 
In recent years, rapid advances in high-throughput DNA sequencing (also known 
as next-generation sequencing, NGS) technologies have enabled the detection of 
chromosomal aberrations and fusion-genes at single base-pair resolution (Campbell et al. 
2008; Maher et al. 2009a; Stephens et al. 2009). Massively parallel RNA sequencing 
(RNA-Seq) of the cellular transcriptome has emerged as a promising approach for the 
identification of previously uncharacterized fusion-gene or “chimeric” transcripts of 
potential functional significance (Maher et al. 2009a; Ozsolak and Milos 2011; Wang et 
al. 2013). Despite these technological advancements, our knowledge about the global 
patterns and complete functional consequences of fusion-genes in cancer is still 
rudimentary. In recent years, the discovery of novel functional and regulatory elements in 
the previously considered ‘gene-desert’ regions of the human genome (Consortium et al. 
2007; Cabili et al. 2011; Prensner et al. 2011)  poses the question if these regions can also 
contribute to the formation of gene-fusions. This dissertation describes studies that 
characterize gene-fusions and resulting chimeric transcripts in breast and ovarian cancer 
using high-throughput transcriptome and whole genome sequencing. I also address the 
bioinformatics challenges associated with the analysis of the massive volumes of 
 xvii 
sequencing data by developing bioinformatics pipelines and more applied integrated 
computational workflows. 
 
Research advance 1: Chapter 2 presents the bioinformatics pipeline called R-SAP 
(RNA-Seq analysis pipeline) that systematically analyze and characterize cancer 
transcriptomes. Multi-threading capability of R-SAP allows rapid analysis. A systematic 
hierarchical characterization R-SAP allows accurate detection of complex fusion 
structures and novel splice-variants as well. 
 
Research advance 2:  Chapter 3 and Chapter 4 describes the design and application of 
computational workflows that integrate R-SAP with specialized set of tool in order to 
perform qualitative as well as quantitative analysis of gene-fusions and underlying 
genomic rearrangements using RNA-Seq and whole genome sequencing data. 
 
Research advance 3:  Analysis of 45 breast invasive carcinoma and 10 healthy breast 
samples using RNA-Seq based transcriptome assembly resulted in the findings indicating 
that an unexpectedly large number of chimeric transcripts are present in both cancerous 
and normal breast tissues and that many of these variants may play a significant role in 
breast cancer onset and development. The study also finds that the ‘gene-desert’ regions 
can also participate in chimeric transcript formation and result in transcriptional de-
regulation of protein-coding genes. 
 
Research advance 4: Whole-genome sequence analysis of six ovarian cancer and six 
matched controls (whole blood) revealed that the structural variants can be of germline or 
somatically derived, and very few of them have potential to form gene-fusions. RNA-Seq 
and gene-expression microarray based analysis indicate that the transcriptional de-





Cancer is a genetic disease 
Cancer is a group of diseases that is characterized by unregulated cell growth and 
spread of abnormal cells in the body. Cancer is one of the most lethal diseases and is 
responsible for 580,350 deaths per year (1600 per day) alone in the US, and an additional 
1,660,290 new cases are expected to be diagnosed this year (ACS 2013).  Research 
efforts for more than a century have established that the genome plays a central role in 
the development of cancer. David von Hansemann, in 1890, found an asymmetric 
distribution of chromosomes as a result of multipolar mitosis or aberrant cell divisions in 
13 carcinoma samples (von Hansemann 1890).  Working with sea urchin eggs, in 1902, 
Theodor Boveri suggested that an “incorrect combination of chromosomes” can enable 
cells to have “unlimited growth” potential and become malignant (Boveri 1914).   
Subsequent work by Robert Schimke showed genome instability and chromosomal 
aberrations resulting in gene amplifications that can render cancer cells drug resistant 
(Schimke et al. 1978).  These findings from the late 19th and early 20th century laid the 
foundation for the theory that cancer is caused by abnormalities in the hereditary 
material. The theory was further supported by the demonstration that agents that damage 
DNA and cause chromosomal alterations cause cancer (Loeb and Harris 2008). 
 
Cancer genomes are characterized by somatic mutations 
Chromosomal aberrations and DNA level changes are collectively called 
‘mutations’.  Depending upon the origin, DNA mutations can be classified as ‘germline’ 
or ‘somatic’. Germline mutations are inherited mutations that may increase susceptibility 
to cancer and lead to familial forms of cancer. For example, mutation in BRCA1 (breast 
cancer 1, early onset) and BRCA2 (breast cancer 2, early onset) genes can increase risk of 
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breast cancer by 20 fold (Harris and McCormick 2010) and nearly 15% of ovarian 
cancers can be attributed to such mutations (Risch et al. 2006). Somatic mutations, on the 
other hand, are DNA level changes acquired during the lifecycle of the cell and passed 
along from the progenitor cells through mitotic division (Stratton et al. 2009).  DNA 
damage in cells is caused by exposure to mutagens such as radiation (including UV 
light), tobacco smoke, naturally occurring chemicals such as aflatoxins (Lengauer et al. 
1998), and oxidative stress within the cell (Cooke et al. 2003). Most of the damage 
caused by mutagens is repaired by the cell; however some may become fixed somatic 
mutations due to inefficient repair mechanisms in the cell and result in cancer. Moreover, 
intrinsic errors in DNA replication can accelerate the rate of somatic changes (Lengauer 
et al. 1998; Stratton et al. 2009).  The first cancer causing somatic mutation was reported 
in the HRAS gene (Harvey rat sarcoma viral oncogene homolog) in a human bladder 
cancer cell line (Reddy et al. 1982). Since then, three decades of research have resulted in 
the discovery of nearly 300 genes that are causatively mutated in cancer (Futreal et al. 
2004; Forbes et al. 2011) and comprise ~1% of all known human genes. Somatic 
mutations are a more prominent cause for cancer progression than inherited mutations. 
90% of cancer genes are somatically mutated, 20% show germline mutations and 10% 
show both [(Futreal et al. 2004) and http://www.sanger.ac.uk/genetics/CGP/Census/]. 
Cancer genomes may harbor hundreds to thousands of somatic alterations but only a few 
of them confer a selective clonal growth advantage and are causally implicated in 
oncogenesis. Such mutations are called ‘driver’ mutations (Greenman et al. 2007; 
Vogelstein et al. 2013) .  The remainders of the alterations are called ‘passenger’ or 
‘bystander’ mutations and may not contribute to cancer development (Futreal et al. 2004). 
However, passenger mutations may be the result of causal mutational mechanisms in 
cancer and hence they can also provide useful insight into the pathogenesis of cancer 
(Pleasance et al. 2010). 
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DNA mutation can encompass a variety of nucleotide changes including point 
mutations that are single base pair substitutions; insertions and deletions of base pairs  
(indels) and genomic rearrangements (also known as large structural variants) involving 
hundreds to millions of base pairs (Lupski and Stankiewicz 2005; Pleasance et al. 2010).  
Genomic rearrangements are gross DNA alterations that collectively represent mutational 
changes including deletion, insertion, inversion, translocation and transposition (Lupski 
and Stankiewicz 2005). Cancer genomes are also subjected to loss or amplification of 
large genomic segments that are collectively referred to as ‘copy number alterations’. 
 
Genomic-rearrangements are a prevalent class of mutations that give rise to gene-
fusions 
Genomic rearrangements (also known as large structural variants) are among the 
most common mutations in cancer (Futreal et al. 2004; Edwards 2010). Cytogenetic 
based research over the last 25 years has resulted in more than 600 registered cases of 
somatic chromosomal rearrangements in cancer (Mitelman 2000). Over 50,000 cases of 
rearrangements in cancer have been reported in more than 11,500 published articles 
(Mitelman et al. 2007). Prevalence of genomic rearrangements can be estimated by the 
fact that every known tumor type contains at least one documented case of 
rearrangement, although the prevalence may vary from 0-100% among patients 
(Mitelman et al. 2007). The most frequent mutation in cancer causing genes is 
chromosomal translocation that results in oncogenic activation (Futreal et al. 2004; 
Stratton et al. 2009). The current catalogue (Forbes et al. 2008) of cancer 
16213703mutations includes 317 out of 522 genes that are mutated by translocation. 
Currently there are 267 known in acute myeloid leukemia, 155 in acute lymphoblastic 
leukemia and 75 in solid tumors.  
Genomic rearrangements typically join normally distant genomic loci and can 
result in fusion-gene structures. Gene-fusions exert their action via transcription where 
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transcribed mRNA is called a “fusion transcript” or “chimeric RNA”. A fusion transcript 
may encode for a fusion protein with oncogenic activity (Rabbitts 1994; Rowley 2001).  
For example, in chronic myeloid leukemia (CML), a reciprocal translocation between 
chromosomes 9 and 22 results in BCR-ABL gene-fusion (Nowell 1962). As a result the 
coiled-coil (CC) oligomerization domain from BCR (breakpoint cluster region) activates 
the tyrosine kinase domain from ABL (Abelson murine leukemia viral oncogene homolog 
1) that drives CML (McWhirter et al. 1993; Ren 2005).  Gene-fusions can aberrantly 
appose enhancer or promoter elements of one gene to another gene without disrupting the 
protein-coding sequence and result in transcriptional deregulation of the latter gene (Look 
1997; Xia and Barr 2005). For example, a deletion on chromosome 21 results in the 
oncogenic activation of ERG gene (ETS-related gene) due to its juxtaposition to 
TMPRSS2 (Transmembrane protease, serine 2) gene’s promoter in prostate cancer 
(Tomlins et al. 2005).  Cancer genomes may harbor several genomic rearrangements that 
may or may not be functional. Although, functional rearrangements give rise to fusion 
RNA by transcription, investigation of genomic aberrations at the transcriptome level is 
very important (Ju et al. 2012).  
Apart from genomic rearrangements, recent studies have discovered two 
additional RNA level mechanisms that can result in gene-fusion transcripts. Co-
transcription or read-through transcription (also known as ‘transcription induced chimera’ 
or TIC), describes two neighboring genes in the genome that are transcribed into a single 
RNA. Inter-genic regions between the two genes and introns are spliced out so that the 
resulting mRNA encodes for a new fusion protein (Akiva et al. 2006; Parra et al. 2006). 
Fusion-gene transcripts can also be generated at the post-transcription level by trans-
splicing of multiple simultaneously processed pre-mature RNAs from different genes 
where the spliceosome ligates exons from two pre-mature RNA molecules in to a single 
mRNA (Sullenger and Gilboa 2002; Garcia-Blanco 2003). 
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Genomic rearrangements and gene-fusions are non-random and sometimes cancer-
specific 
Genomic rearrangements were initially considered to be random events that occur 
by chance and when selected, lead to oncogenesis (Savage 1993; Mitelman et al. 2007). 
But recent studies have suggested that genomic rearrangements are triggered by factors 
such as chemical and radiation exposure, faulty DNA repair pathways and DNA 
replication errors that are also responsible for cancer initiation.  
Influences that trigger the genesis of genomic rearrangements are well known now and 
can be divided them into four categories that work synergistically in cancer  (Aplan 2006; 
Mani and Chinnaiyan 2010). First, spatial proximity in the nucleus where rearranged 
genes are brought in close proximity in a cell-type and cell division-stage specific 
manner, and close proximity correlates to the frequency of translocation (Roix et al. 
2003). Second, cellular stress, including genotoxic stress (chemical and radiation 
exposure) (Fugazzola et al. 1995), oxidative stress (Barzilai et al. 2002) and replicative 
stress (Tuduri et al. 2009) that cause double strand breaks and set off the formation of 
genomic rearrangements (Richardson and Jasin 2000)(10864328). Third, inefficient DNA 
damage response and faulty repair mechanisms of DNA breaks result in genomic 
rearrangements (Boboila et al. 2010; Simsek and Jasin 2010). And fourth, DNA sequence 
features such as the presence of repetitive sequences, palindromic sequences, CpG 
dinucleotide, and epigenetic modifications, are also known to increase the probability of 
genomic rearrangement (Ng et al. 2003; Tsai et al. 2008; Huang et al. 2010).  
There are three known cellular mechanisms underlying genomic rearrangements: 
Non-allelic homologous recombination (NAHR) where low-copy repeats cause 
recombination between two otherwise un-related genomic regions; non-homologous end-
joining (NHEJ) is the faulty double strand DNA break repair that ligates distant genomic 
loci; and third, replication fork stalling and template switching (FoSTeS) where the 
lagging DNA strand is switched during replication (Aplan 2006; Gu et al. 2008). Insights 
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into the genesis and cellular mechanisms underlying genomic rearrangements and gene-
fusions suggest that the onset of cancer is accompanied by genomic rearrangements since 
they share common factors of initiation. The causal role of gene-fusions and their 
specificity to cancer further underscores their potential as biomarkers of cancer onset and 
progression. 
 
Gene-fusions are employed as biomarkers and therapeutic targets in cancer 
Gene-fusions represent the most common class of mutations that are detected in 
almost every tumor type (Rowley 2001). Recurrent gene-fusions, in particular, 
considered as ‘driving’ or causal mutations are perceived as potential biomarkers and 
therapeutic targets in cancer (Mitelman 2000; Laxman et al. 2008).  The first consistent 
chromosomal rearrangement, known as the ‘Philadelphia chromosome’, was discovered 
in chronic myeloid leukemia (CML) by Nowell and Hungerford  in 1962 (Nowell 1962).  
This rearrangement results in the BCR-ABL gene-fusion resulting in oncogene activation 
and is observed in 95% of CML patients.  CML patients with this disorder are 
administered a tyrosine kinase inhibitor drug, imatinib, to treat the disease.  Similarly, the 
proto-oncogene, c-MYC, is activated in 90% of the Burkitt’s lymphoma as a result of 
translocation to immunoglobulin genes (Cory 1986). Gene-fusions have been 
predominantly observed in hematological malignancies, mainly leukemias and 
lymphomas, and soft tissue sarcomas, but their application in solid tumors has been 
limited (Kumar-Sinha et al. 2008).  For example, all solid tumors and epithelial 
carcinomas account for 80% of the cancer related deaths but they make up only 27% of 
the known cases of karyotypic abnormality and rest is attributed to hematological 
disorders[ (Kumar-Sinha et al. 2006; Mitelman et al. 2007), 
http://cgap.nci.nih.gov/Chromosomes/]. This discrepancy may seem to indicate that 
genomic rearrangements are rare in solid tumors. In reality, chromosomal aberrations in 
solid tumors underrepresented due to the poor chromosomal morphology, presence of 
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cytogenetically unrelated clones and presence of very complex karyotypes in solid tumor 
samples that make them less amenable to the traditional karyotyping methods (Gorunova 
et al. 1998; Kumar-Sinha et al. 2006). Despite technological barriers, advancement in 
biological assays and high-throughput genomics has led to major discoveries of several 
recurrent fusion genes in solid tumors and other epithelial carcinomas (Edwards 2010). 
The first breakthrough was achieved by (Tomlins et al. 2005) when they discovered the 
presence of TMPRSS2-ERG (Transmembrane protease, serine 2 and ETS-related gene) 
gene-fusion in more than 50% of localized prostate cancers.  The ERG gene is an 
oncogenic transcription factor that becomes overexpressed as a result of fusion with the 
5’UTR from TMPRSS2.  Other examples of well documented gene-fusion biomarkers in 
solid tumors include ETV6-NTRK3 (ets variant gene 6 and neurotrophic tyrosine-kinase 
receptor type 3) that was originally detected in congenital fibrosarcoma and later detected 
in secretory breast carcinoma (Knezevich et al. 1998; Tognon et al. 2002). A gene fusion 
between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic 
lymphoma kinase (ALK) was first discovered in non-small cell lung carcinoma and it is 
observed in 3-13% of the lung cancer patients (Soda et al. 2007). Another example is the 
gene-fusion RET-NTRK1 (receptor tyrosine kinase and neurotrophic tyrosine kinase 
receptor) that is detected in as many as 50% of thyroid papillary carcinomas (Bongarzone 
et al. 1998; Pierotti 2001).  Other solid tumors that have at least one reported biomarker 
gene-fusion include breast, pancreatic, colon, ovarian and brain tumors (Kumar-Sinha et 
al. 2006).  Although, the current list of gene-fusion biomarkers for solid tumors is not as 
comprehensive as hematologic malignancies, advancement in the sensitivity of the 
analytical genomics assays will reveal more widespread occurrences of recurrent gene 




High-throughput DNA sequencing has accelerated the discovery of gene-fusions and 
their global patterns in cancer 
Early methods to identify genomic rearrangements and gene fusions were high 
resolution cytogenetic-based, such as spectral karyotyping followed by fluorescent in situ 
hybridization (FISH) or noncytogenetic-based methods such as the modified NIH 3T3 
transformation foci assay (Kaye 2009). Development in biological assays led to the 
application of array based methods such as aCGH (array comparative hybridization) for 
the detection of gene-fusions but these methods are limited in their throughput and 
resolution of detection. In recent years, rapid advances in high-throughput DNA 
sequencing (also known as next-generation sequencing, NGS) technologies have enabled 
the detection of chromosomal aberrations and fusion-genes at single base-pair resolution 
(Campbell et al. 2008; Maher et al. 2009a; Stephens et al. 2009) .  NGS allows 
sequencing of the fragments of target molecules such as DNA or RNA in a massively 
parallel way that generates millions to billions of short (50 – 150 bp) reads. The 
sequencing protocol typically follows the clonal amplification of the target sequences so 
that the output provides a multi-fold coverage (Metzker 2010). Currently available NGS 
technologies such as Illumina Hi-Seq, Ion torrent and Pacific Biosciences also allow 
sequencing of the cellular transcriptome that harbors expressed fusion genes known as 
fusion-gene transcripts or chimeric transcripts (Martin and Wang 2011). Sequencing of 
the transcriptome is called RNA-Sequencing or RNA-Seq (Wang et al. 2009). Since 
functional mutations in cancer are manifested through transcription, investigation of 
genomic aberrations at the transcriptome level becomes very important in isolating 
functional or potential driver mutations from the non-functional mutations (Ju et al. 
2012). 
Deep coverage RNA-Seq provides a comprehensive view of the transcriptome 
that enables researchers to systematically analyze cancer cell transcriptomes and uncover 
novel and potentially oncogenic fusion-gene transcripts (Maher et al. 2009a; Ozsolak and 
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Milos 2011; Wang et al. 2013). For instance, Maher et al. applied short and long read 
RNA-Seq to rediscover BCR-ABL1 in CML cell lines, TMPRSS-ERG in prostate cancer 
and additionally, reported multiple novel fusion transcripts associated with prostate 
cancer. Targeted sequencing of prostate cancer using  artificial exon-exon junctions  
uncovered six recurrent TIC (transcription induced chimeras) or read-through gene-
fusion events including SLC45A3-ELK4 that is already a known frequent erythroblast 
transformation-specific fusion in prostate cancer (Nacu et al. 2011). Studies involving 
RNA-Sequencing of large number of cancer samples have begun to reveal global patterns 
and the underlying molecular mechanisms of fusion-genes in solid tumors. For example, 
transcriptome sequencing of 24 breast cancer samples resulted in the detection of 15 
primary breast tumor subtype specific fusion-gene transcripts (Asmann et al. 2012). 
These fusion-gene transcripts can serve as potential biomarkers for breast-cancer 
stratification for further targeted therapy. Recently,  sequencing of  89 samples (79 breast 
cancer and 10 normal samples) discovered  gene fusions that were recurrent in 4-6% of 
the patients and involved MAST1 and MAST2 genes, and NOTCH-family genes that also 
increased the proliferation of benign breast cancer cells (Robinson et al. 2011).  
The increasing feasibility and the rapidly decreasing cost of sequencing have 
already paved the way for its routine application in cancer research (Voelkerding et al. 
2009). Although, unprecedented amounts of data from cancer transcriptomes provides a 
new opportunity to uncover novel gene-fusions, it comes with bioinformatics challenges 
that need to be addressed.  The cancer transcriptome is inherently complex as it contains 
novel RNA species such as fusion transcripts and splice-variants generated as a result of 
genomic mutations and transcriptional deregulation (Carninci et al. 2008; Costa et al. 
2010). Hence the massive amounts of RNA-Seq data from cancer transcriptomes requires 
systematic analysis using high-performance bioinformatics tools that can address both 
complexity and massiveness of the sequencing data at the same time. In order to address 
this challenges we developed and automated multi-threading RNA-Seq analysis pipeline 
 10 
(R-SAP; described in CHAPTER 2; (Mittal and McDonald 2012)) that follows a 
systematic and hierarchical characterization scheme to qualitatively and quantitatively 
analyze RNA-Seq data from cancer cell transcriptomes. In CHAPTER 3, we apply R-
SAP to analyze 45 breast cancer transcriptomes in order to uncover global patterns of 
chimeric transcripts in cancer. In this chapter we create an integrated analysis workflow 
using R-SAP and currently available bioinformatics tools for with highly specialized 
functionality such as transcriptome assembly, RNA expression estimation and reference 
genome alignment. In CHAPTER 4, we expand the applicability of R-SAP to discover 
genomic rearrangements using whole genome sequence data from six ovarian cancer 
genomes and perform a comparative analysis with the gene-fusions detected in the 
transcriptome of the same patients. 
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CHAPTER 2 
R-SAP: A MULTI-THREADING COMPUTATIONAL PIPELINE FOR THE 




The rapid expansion in the quantity and quality of RNA-Seq data requires the 
development of sophisticated high-performance bioinformatics tools capable of rapidly 
transforming this data into meaningful information that is easily interpretable by 
biologists. Currently available analysis tools are often not easily installed by the general 
biologist and most of them lack inherent parallel processing capabilities widely 
recognized as an essential feature of next-generation bioinformatics tools. We present 
here a user-friendly and fully automated RNA-Seq analysis pipeline (R-SAP) with built-
in multi-threading capability to analyze and quantitate high-throughput RNA-Seq 
datasets. R-SAP follows a hierarchical decision making procedure to accurately 
characterize various classes of transcripts and achieves a near linear decrease in data 
processing time as a result of increased multi-threading. In addition, RNA expression 




The cellular transcriptome is the complete set of protein coding mRNAs, non-
coding RNAs and other regulatory RNAs present in a cell (Velculescu et al. 1997). In 
eukaryotes, the complexity of the cellular transcriptome is enhanced by the presence of 
alternatively spliced RNAs, fusion and other types of chimeric transcripts and transcripts 
encoded within previously uncharacterized genomic regions (Carninci et al. 2008; Costa 
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et al. 2010). The complexity of the transcriptome of cancer and other diseased cells can 
be even more complex due to deregulation of the cellular splicing machinery, and the 
transcription of various genomic mutations that contribute to aberrant cell function 
(Skotheim and Nees 2007; Ritchie et al. 2008). For these reasons, transcriptome profiling 
has become an important tool, not only in the diagnosis of cancer and other diseases, but 
additionally for the identification of putative molecular targets for therapeutic 
intervention (Aparicio et al. 2000; Sutherland et al. 2011).   
 
While transcriptomics was first heralded by the introduction of microarray 
technologies over two decades ago (Kulesh et al. 1987; Maskos and Southern 1992), the 
field is currently undergoing revolutionary expansion by virtue of the application of deep-
sequencing technologies to the quantitative and qualitative characterization of cellular 
transcripts (Morozova and Marra 2008). Commonly referred to as “RNA-Seq”, these 
high-throughput methodologies involve the massively parallel sequencing of millions of 
copies of fragments of cellular transcripts (Wang et al. 2009). Contemporary sequencing 
platforms can generate megabytes to gigabytes of data in a single sequencing run 
(Morozova and Marra 2008). This magnitude of data not only allows for the 
characterization of moderate to high abundant transcripts, it also provides sufficient 
coverage and depth to characterize rare and potentially novel low abundant transcripts 
that went undetected by earlier methodologies.  
 
The rapid expansion in the quantity and quality of RNA-Seq data requires the 
development of sophisticated high-performance bioinformatics tools capable of rapidly 
transforming this data into meaningful information that is easily interpretable by 
biologists. Current approaches to the analysis of RNA-Seq data involve the alignment of 
sequencing reads to a reference genome and subsequent association of these genome 
mappings with established transcript models to quantify expression levels and detect 
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mRNA isoforms, fusion genes and other novel transcript structures (e.g., (Mortazavi et al. 
2008; Pan et al. 2008; Sultan et al. 2008; Guffanti et al. 2009; Maher et al. 2009b; Berger 
et al. 2010; Robertson et al. 2010)). Despite their obvious utility, currently available 
analysis tools are not easily installed by the general biologist and most of them lack 
inherent parallel processing capabilities widely recognized as an essential feature of next-
generation bioinformatics tools (McPherson 2009; Richter and Sexton 2009).  
 
We present here an automated RNA-Seq analysis pipeline (R-SAP) with built-in 
multi-threading capability to analyze and quantitate high-throughput RNA-Seq datasets. 
R-SAP is easy to install and follows a hierarchical decision making procedure to 
characterize various classes of transcripts. It compares reference genome alignment of 
sequencing reads with sets of well-annotated transcripts in order to detect novel isoforms. 
Reads that map completely within known exon boundaries are used for gene expression 
quantification. Fragmented alignments of sequencing reads are used to detect chimeric 
transcripts such as fusion genes. Novel exons detected within previously annotated inter-
genic and intronic regions are also reported. R-SAP modules can be customized by a 
user-adjustable set of parameters for particular applications. R-SAP generates output files 
that contain transcript assignments for the sequencing reads, gene expression levels, lists 
of aberrantly spliced genes and data statistics. The computational outputs can be viewed 
with online genome browsers by uploading the R-SAP generated browser compatible 
output file. To demonstrate the applicability of the pipeline, we analyzed publically 
available RNA-Seq data generated from the Roche 454 and the Illumina GA platforms.  
We achieved a linear decrease in the data processing time as a result of increased multi-
threading. RNA expression level estimates obtained using our pipeline displayed high 
concordance with levels measured by microarrays. R-SAP program is publicly available 
at www.mcdonaldlab.biology.gatech.edu/r-sap.htm. 
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In the following sections, we describe the architecture of the pipeline and results from the 
analysis of the test data to evaluate various modules of the pipeline.  
 
Materials and Methods 
Overview of the pipeline: 
R-SAP compares reference genome mappings of RNA-Seq reads with the 
genomic coordinates of known and well-annotated transcripts (reference transcripts or 
known transcript models) in order to detect known and new RNA isoforms and, chimeric 
transcripts. There are four core modules in R-SAP’s workflow (Figure 2.1): (i) initial 
alignment screening, (ii) characterization with reference transcripts (iii) chimeric 
transcript detection and (iv) RNA expression quantification.  A main wrapper script 
controls the flow of data to these core modules (Figure 2.1).  
 
 
To initiate analyses using R-SAP, the user provides two required inputs for the 
pipeline:  the sequence alignment file and known transcripts’ coordinate file. Currently 
R-SAP accepts alignment files only in psl format that are generated by mapping RNA-
Seq reads to the reference genome using BLAT (Blast like alignment tool) (Kent 2002) or 
SSAHA2 (Sequence search and alignment by hashing algorithm) (Ning et al. 2001). 
Figure 2.1. Architecture of R-SAP and data flow in the pipeline.  Wrapper script 
begins the execution of the pipeline and divides the data in to smaller sub-sets. Multiple 
threads are created and each core module in each thread is run under the “Control-
module”. Output files are merged by the wrapper script and corresponding output files 
are written to the disk. 
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RNA-Seq reads mapping to the genome may result in the alignments scattered across 
multiple exons separated by introns.  We chose psl as the alignment format for the 
pipeline because the scattered alignments are precisely stitched together and reported as a 
large single alignment.  As a result, for each sequencing read the most likely alignment 
and corresponding genomic locus can be readily found in the alignment files. Moreover, 
the psl format preserves the orientation of alignment blocks originating from the 
contiguous genomic loci enabling their accurate re-mapping to the annotated exons and 
determination of associated reference structural variants. 
 
R-SAP is also configured to work with two of the currently available transcript 
assemblers: Cufflinks (Trapnell et al. 2010) and Scripture (Guttman et al. 2010). 
Assembled transcripts can be supplied to R-SAP either in GTF (Gene Transfer Format) 
or in BED (Browser Extensible Data) format. GTF and BED are default output formats 
from Cufflinks and Scripture respectively. 
 
Known transcript model files for the reference genome can be obtained from the 
UCSC genome database (Fujita et al. 2011), the UCSC table browser (Karolchik et al. 
2004) or the Ensembl database (Hubbard et al. 2002). R-SAP accepts known transcript 
model file formats in standard table browser format, GTF or BED. The analysis 
stringency can be adjusted using a set of cutoff and threshold values (described in 
Supplementary Methods) provided by the user at the beginning of the pipeline.  
 
R-SAP begins with the parsing of input data files for the format check and 
verification of the input parameters using the main wrapper script. The same wrapper 
script then divides the input alignment file into the number of parallel threads specified 
by the user (default is one thread). Each part of the input file is supplied to the set of core 
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modules, in parallel. At the completion of each thread run, the main wrapper script 
merges the intermediate output files and creates the final set of output files.  
 
(a) Alignment screening:   
  The first step in the pipeline is to select the most likely alignment for each of the 
sequencing reads as reads may have multiple genomic hits. Alignment hits with the 
highest alignment identity, alignment score and read coverage among all the genomics 
hits are selected as the best alignments (top-scoring) on the genome (see Supplementary 
Methods). Top-scoring alignments are then classified as high-scoring if they have only 
one best possible alignment with identity and read coverage values above the cutoff 
(default 95% and 90%, respectively). Reads that map to multiple genomic loci with 
equivalent alignment identity and read coverage are classified as multi-hit reads.  Those 
reads that produce low quality alignments with identity and/or read coverage below the 
threshold values are further analyzed by a separate module of the pipeline to detect 
chimeric transcripts (see below). The remaining reads that are low quality alignments are 
classified as “discarded”. Both “discarded” and multi-hits reads are excluded from the 
further analysis and reported separately.  
 
(b) Characterization with reference transcripts:   
  High-scoring reads from the alignment module are subjected to the 
characterization module where genome mapping coordinates of the sequencing reads are 
precisely compared with the transcriptional and exons boundaries of the well annotated 
transcripts. Mapping of a read within the known exon boundaries is considered as 
indicative of normal splicing whereas out of exon or partial exon mapping is indicative of 
aberrant splicing or the presence of a novel isoform. The characterization strategy is 
outlined in Figure 2.2. Read alignments that skip exonic bases because of discontinuous 
blocked alignment on the reference genome are characterized as exon-deletions in that 
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reference transcript (Figure 2.2B, C). Small deletions (10 bp by default) are permitted in 
the alignment in order to tolerate small gaps due to the sequencing errors. Read 
mappings, that span multiple exons are used to detect exon-skipping events (Figure 
2.2D).  
  Partial mapping of the sequencing reads onto known exons results in either gene 
boundary expansion (Figure 2.2E,F) or extension of exons into introns (Figure 2.2G,H).  
Slight extensions in the alignment beyond the exon boundary are tolerated by applying 
minimum exon extension cutoff (2 bp default). 
 
  Sequencing reads that extend 5’ terminal exons (5’UTR) into upstream promoter 
regions (Figure 2.2E) are considered the result of potential new transcription start sites 
(alternative TSS). Similarly, reads that extend 3’ terminal exons (3’UTR) into 
downstream regions are characterized as potential alternative polyadenylation site 
variants (Figure 2.2F).  Intron-retentions (or complete intron inclusion) are detected when 
a read alignment completely spans an intron including at least part of flanking exons 
(Figure 2.2H). Such events are included in the internal-exon-extensions characterizations.  
Reads mapping completely within introns are characterized as intron-only reads (Figure 
2.2I).  Sequencing reads that do not map to any known transcript and fall within a pre-
specified gene -radius (5 kb default setting), on either side of the transcript, are 
characterized as neighboring-exons (Figure 2.2J). Clusters of such reads may represent 
the existence of new transcriptional boundaries and can be aggregated with the known 
transcript models. Reads falling outside the gene-radius are designated as gene-desert 
reads (Figure. 2.2K).  Some of the high-scoring reads may exhibit multiple 
characterizations with the reference transcripts.  For example, a read may exhibit internal-
exon-extension simultaneously with a 5’ UTR expansion. Such reads are sub-
characterized as multiple-annotation reads. We apply one additional stringency criterion 
during the characterization step to further filter out possible sequencing artifacts. 
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Sequencing reads that expand the transcript boundary by more than 100 kb or have 
alignment blocks separated by more than the cutoff distance value (100 kb default 




  As a default setting, the pipeline characterizes each read with only one best fitting 
reference transcript. The best fitting transcript is the one with maximum exon overlap and 
minimum non-exonic regions (intron and intergenic) overlap with the read. Reference 
transcripts with protein-coding potential are selected over the non-protein-coding 
transcripts. In cases where multiple transcripts are equally likely, the best fitting 
transcript is selected randomly. The pipeline provides the user with the option to 
inactivate all of these defaults settings in which case all possible reference transcript 




Figure 2.2. Characterization strategy of R-SAP for high-scoring reads. Read 
mappings (black boxes) are compared with the known exon (empty boxes) and intron 
(black lines). The larger empty boxes represent coding regions while the smaller empty 
boxes represent untranslated regions. A. Read mapping  within the known exon. B,C. 
Discontinuous blocked alignment resulting in exonic base skipping (dashed-line  box).  
D. Skipping of third exon. Exon skipping is also characterized as exon-deletion. E.  
Extended 5’UTR. F.  Extended 3’UTR. G, Exon  extended into intron. H.  Intron 
retention . I. Read mapping completely within the  intron. J. Read mapping outside the 
permissible (d) gene-radius  K. Read mapping outside the permissible (d) gene-radius. 
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(c) Chimeric transcript detection:  
  Chimeric transcripts may be due to genomic rearrangements such as 
translocations and inversions, or transcriptional processes such as co-transcription, trans-
splicing or aberrant intra-genic (within the same gene) splicing (Flouriot et al. 2002; 
Mitelman et al. 2005; Guffanti et al. 2009; Maher et al. 2009b). Sequencing reads from 
chimeric transcripts are very likely to produce discrete alignments to distant or close 
genomic loci. In order to detect candidate chimeric reads, all the reads with top-scoring 
alignments displaying low query coverage (below the cutoff coverage value, default 
90%) and an alignment identity greater than the cutoff value (default 95%) are selected. 
These reads are considered potential chimeric reads only if the region not covered in the 
top-scoring alignment of the read is at least 20 bp (default gap threshold). Twenty bp was 
selected as the default setting because alignment algorithms will not produce a significant 
alignment for the relatively short remaining part of the read. Once the above criteria are 
met, alignments are parsed to obtain the alignment pair for the top-scoring alignment 







 Alignments are filtered out if the alignment identity is less than the cutoff identity 
value (default 95%).  The alignment with the highest coverage on the remaining part of 
the read and with highest alignment identity is selected as the best possible pairing 
alignment. In addition, intra-chromosomal pairing is preferred over inter-chromosomal 
pairing.  Small overlaps (less than one third of alignment pair’s coverage on remaining 
part of the read) and gaps (not more than the gap-threshold, 20 bp default) between the 
two read segments corresponding to alignment pairs are allowed. To ensure the validity 
and significance of the alignment, chimeric read segments are required to be at least 25 
bp long. Thus, chimeric reads shorter than 50 bp are rejected. False positives are further 
minimized by excluding chimeric reads that produce alignments from repetitive genomic 
regions. If more than one hit are identified for any part of a chimeric read with identity 
above the cutoff value and with more than 90% coverage on the same region of read 
sequence, the candidate chimeric transcript is rejected as a false positive. The remaining 
alignment pairs are associated with reference transcripts and categorized in various 
Figure 2.3. Schematic diagram of the detection and annotation of chimeric 
transcripts by R-SAP using fragmented genomic alignments. A. Best possible 
alignment pairs are selected for the reads displaying significant sequence similarity to the 
reference genome. Alignment fragments are then individually compared with known 
transcript models. B. Alignment pairs belong to two different genes (inter-chromosomal 
or intra-chromosomal). C. Alignment pairs mapped to the same gene but in opposite 
orientation on the reference genome. D. Both pairs mapped within the same gene but 
their order on the sequencing read is opposite of their alignment order on the 
corresponding gene.  E, F. At least one alignment pair mapped to the genomic region 
with no known gene from the reference gene set. 
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chimeric read structures according to the genic or intergenic regions to which they map 
(Figure 2.3B-F).  
 
(d) Expression level quantification:  
  Reference transcript assignment information for exon-only and intron-only reads 
is consolidated from multiple threads into a single file. Expression levels are quantified 
using the RPKM (reads per kilobase of exon model per million mapped reads) method 
proposed by Mortazavi et al. (Mortazavi et al. 2008). Transcript level RPKM values are 
calculated using exon-only reads and similarly the RPKM value for each individual 
intron is calculated using intron-only reads. R-SAP estimates expression values only if 
the input alignment file is provided in psl format. Since, assembled transcript files do not 
contain read level mapping information, expression estimation is not possible using these 
files.  
  Once each of the above modules are run, annotation and data statistics are 
collected from various intermediate output files and merged to generate the final output 
files. The final set of output files contains RNA level expression files, assignment of 
known transcripts to the high-scoring reads and their characterization, chimeric reads 
with annotation and data statistics files with distribution of reads over the various classes. 
Finally, browser compatible out-put files containing annotation information of all the 
reads are generated that can be uploaded to web based genome browsers (such as UCSC 
and Ensembl) for the visualization purposes. 
 
Implementation and requirements: 
  R-SAP was implemented using Perl 5.8.0 (also the minimum version of perl 
required to run the pipeline) enabled with multi-threading and is compatible with all 
UNIX and Windows based systems. Disk space required during the pipeline run is 1.5 X 
the size of the input alignment file.  
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Test datasets 
  MAQC Universal Reference Human data: The MAQC Universal Reference 
Human Poly-A+ selected RNA-Seq data compiled from Mane et al. (Mane et al. 2009) 
was obtained from Short Read Archive (SRA accession SRX002934). The data consisted 
of 881,555 of Roche’s 454 sequencing reads with an average length of 258 bp from five 
454 GS-FLX sequencing runs. 878,275 of those reads were retained after low-complexity 
repeat trimming and short read (<20 bp) exclusion (see Supplementary Methods). Raw 
microarray data (Affymetrix Human U133Plus2.0) was downloaded from the Gene 
Expression Omnibus (GEO accession: GSM589512). Four replicates of TaqMan qRT-
PCR measurements for the same sample were also obtained from Gene Expression 
Omnibus (GEO accessions: GSM129641, GSM129640, GSM129639 and GSM129638) 
that consisted of expression values for 1044 probes. 
 
ENCODE lymphoblastoid cell line data:  
  As a short read ultra high-throughput data set, RNA-Seq data for Gm12878 
(lymphoblastoid cell line) from ENCODE project (Birney et al. 2007) was downloaded 
from hgdownload.cse.ucsc.edu /goldenPath/hg19/encodeDCC/wgEncode 
CaltechRnaSeq/wgEncodeCaltechRnaSeqGm12878R2X75N 
aIl200FastqRd1Rep1.fastq.gz. The data file contained a total of 87929372 paired-end 
Illumina GA reads of read length 75-bp. Microarray intensities (Affymetrix Human Exon 
1.0 ST chip) for the same sample were obtained from GEO (accession: GSM472901).   
 
NCBI nucleotide data:  
  We searched ChimerDB 2.0 (Kim et al. 2010) to obtain the GenBank accession 
IDs of the publicly available sequences that are considered chimeric transcripts. Because 
these chimeric transcripts were computationally detected, we limited the dataset to the 
high confidence set of chimeric transcripts by choosing only those chimeric transcripts 
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that also represented fusion gene pairs in the literature based annotation from ChimerDB 
2.0. In this way, we obtained 206 accessions IDs whose sequences were drawn from the 




  All RNA-Seq reads and GenBank sequences were mapped to the reference human 
genome (hg18) using BLAT with the default parameters settings for the DNA sequence 
alignment in BLAT. We used RefSeq (Pruitt et al. 2007) transcripts (hg18) as our 
reference set and the corresponding genomic coordinates were downloaded using UCSC 
Table browser. 
  To demonstrate the applicability of R-SAP, a complete pipeline run was 
performed on the MAQC Reference Human RNA-Seq dataset. For the evaluation of 
pipeline’s expression estimation and isoform detection performance, we employed the 
ENCODE Gm12878 cell line RNA-Seq dataset in addition to MAQC RNA-Seq dataset. 
The high confidence chimeric transcript dataset obtained from Chimer DB 2.0 and NCBI 
was used for testing R-SAP’s chimer-detection module. To evaluate R-SAP’s RNA-seq 
quantifications, the output was compared with the results of microarray gene expression 
analyses and TaqMan qRT-PCR measurements carried out on the same cells. R-SAP’s 
expression estimation performance was benchmarked using the same RNA-Seq datasets 
against Cufflinks (Trapnell et al. 2010) and RSEM (Li and Dewey 2011) while isoform 
predictions were compared with those from Trans-ABySS (Robertson et al. 2010) and 
Cufflinks.  Data analyses and comparison methods used for the different platforms and 
programs are summarized in Supplementary Methods. 
  We performed R-SAP test runs using the default parameter settings (described in 
Supplementary Methods) of the pipeline. These default values were previously derived 
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and optimized empirically during the development of R-SAP by running core modules 
individually on various RNA-Seq datasets (data not shown here).  
 
Results and Discussion 
Demonstration of the applicability of R-SAP using the MAQC dataset 
  Sequencing tags from the test MAQC Reference Human RNA-Seq dataset were 
initially mapped to the human reference genome. We mapped 855,159 (97.3% of the 
878,275 cleaned reads, Table 2.1) and analyzed these alignments using R-SAP.  More 
than half (491,117/855,159 or 57.43%) of the mapped reads were high-scoring (Table 






Table 2.1. Results of initial mapping and alignment screening of MAQC Reference 




Total raw sequencing reads 881,555 
Cleaned reads 878,275 
Genome mapped reads 855,159 
 
Classification 
Reads (% genome 
mapped reads) 
 
High-scoring 491,117 (57.43%) 
Chimers 8,458 (0.99%) 
Multi -hits 29,279 (3.42%) 





   
  As expected from the RNA-Seq data, the majority (299,473/491,117 or 61%) of 
the high-scoring reads mapped to the exons (Figure 2.4, Table 2.2). Slightly more than 
half (54.42%; 267,279/491,117) of high-scoring reads were exon-only reads that could be 
attributable to 24,461 RefSeq transcripts (Table 2.2). RPKM values (expression levels) 
for these RefSeq transcripts are presented in Table A.10. R-SAP identified a wide 
spectrum of expression values RPKM values) ranging from a minimum of 0.046 for the 
TTN (titin or connectin) gene to a maximum of 2,112 for the MTRNR2L2 (humanin- like 
protein 2) gene.  More than 1% (1.38%; 6,786/491,117) of the high-scoring reads were 
found to be associated with exon-deletion events among the 4,850 of the RefSeq 
transcripts (Table 2.2). Relatively few (840/6,786 or 12.37%) of the events characterized 
by R-SAP as exon deletions were attributable to exon-skipping events corresponding to 
620 RefSeq transcripts. While skipping of a maximum of 20 exons was observed, the 
majority of the exon skipping events involved skipping of only one exon (Figure 2.5). It 
is important to note that the power and accuracy of R-SAP to detect splice variants 
Table 2.2. Number (%) of high-scoring reads (obtained from MAQC Reference 
Human dataset) partitioned by R-SAP into sub-categories. Also, shown is the number 
of RefSeq transcripts represented in each sub-category. 
 
Sub-categories  
(characterization)   
Reads  (% high-scoring) Represented RefSeq  
transcripts 
 
Exon-only 267,279 (54.42%) 24,461 
Exon-deletion 6,786 (1.38%) 4,850 
AlternativeTSS 1,210 (0.25%) 1,078 
Alternative Polyadenylation 2,759 (0.56%) 2,042 
Internal-exon-extension 18,419 (3.75%) 7,648 
Multiple-annotations 3,020 (0.61%) 1,973 
Intron-only 104,824 (21.34%) 22,383 
Neighboring-exons 17,935 (3.65%) 5,929 
Gene-desert 66,694 (13.58%)  
Uncharacterized   2,191 (0.45%)  
 




depends completely upon the length of the sequencing reads. For instance, exon-skipping 
events are detected when the read spans the flanking exons of the skipped exon.  Short 
reads from such new splice junctions will not produce significant alignments on the 
genome and hence will go undetected. Previously published RNA-Seq studies detect 
exon skipping by mapping the short reads to synthetically created library of new splice 




We observed that internal-exon-extension (3.75%, Table 2.2) accounted for more 
than the extension of known transcription boundaries (AlternativeTSS and 
AlternativePolyadenylation) combined (0.25% + 0.56%, Table 2.2). These transcriptional 
events can be further examined in the follow-up analysis.  
Figure 2.4. Distribution of the high-scoring reads from MAQC Reference Human 
dataset onto RefSeq transcripts. “Exons” includes those reads characterized as Exons-
only, Exon-deletion, Alternative TSS, AlternativePolyadenylation, Internal-exon-
extension and Multiple-annotations. “Intergenic” includes those reads characterized as 
gene-desert or neighboring-exon, “Introns” represent reads mapping completely within 
introns and “Uncharacterized” are those reads that cannot be characterized with any 




For example, internal-exon-extension in the last intron or extension of 3’end of 
the transcript is indicative of the potential alternative polyadenylation site. Presence of 
poly-A tail or poly-T prefix on the reads may confirm the presence of polyadenylation 
site (Nagalakshmi et al. 2008). Internal-exon-extension reads also included 361 reads that 
showed retention of 305 introns in 275 of the RefSeq transcripts (Table A.3).  
 
 The second most frequent category of high-scoring reads identified by R-SAP 
(21.34%, Table 2.2) was intron-only reads. While intron-only reads may occasionally 
result from the presence of premature mRNAs containing un-spliced introns in 
sequencing samples, intron-only reads that are in high abundance may be indicative of 
yet-to-be annotated exons. In an effort to separate these potentially new “intronic exons” 
from un-spliced introns, RPKM values for each intron is calculated using intron-only 
reads. Introns with RPKM values of the same order of magnitude as the RPKM value of 
the corresponding annotated transcript are reported by R-SAP as potentially new intronic-
exons.  Our pipeline reported 9,707 introns containing potentially new exons that 
correspond to 5,890 of the RefSeq transcripts (presented in Supplementary File S3).  
Figure 2.5. Frequency of exon skipping in high-scoring reads from MAQC 
Reference Human dataset. A total of 893 sequencing reads resulted from the skipping 
of 1191 exons corresponding to 645 Hg18 RefSeq known transcripts. 
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About 3% (17,935/491,117) of the high-scoring reads were characterized as neighboring-
exons (Table 2.2).  Further examination revealed that the distribution of neighboring-
exons was biased downstream of 3’end of the RefSeq transcripts relative to the 5’ end 
(70% 3’end and 30% 5’ end)  
 
 Gene-desert was the third most abundant category (13.58%, 66,694/491,117) of 
the high-scoring reads (Table 2.2). The remaining ~1% of the high-scoring reads were 
delegated to either the multiple-annotations (0.61%, Table A.4) or uncharacterized 
(0.45%) category (Table 2.2). Uncharacterized were those that could not be associated 
with any known reference transcript by the pipeline. Examples for each type of 































As MAQC Reference Human sample was obtained from a pool of cancer cell 
lines (Supplementary Materials of (Shi et al. 2006)) and since cancer cells have been 
previously reported to harbor chimeric transcripts (Mitelman et al. 2005), we expected to 
observe such transcripts in our test dataset. R-SAP characterized 8,458 reads (~ 1% of the 
855,159l mapped reads) as the chimeric transcripts (Table 2.1). This relative low 
abundance of chimeric transcripts is consistent with the fact that prevalence of such 
RNA-species is reported to be typically low (37,38). These designated chimers were 
further characterized by R-SAP as inter-chromosomal (51.1%) or intra-chromosomal 
(48.9%) based on the target genomic regions of the alignment pairs in the chimeric 
transcripts (Table 2.3).  Nearly 40% of the detected chimeras were intra-genic (type -1 
Figure 2.6. Examples of various sub-categories characterized by R-SAP from the test 
MAQC Reference Human dataset as they are displayed in the UCSC genome browser 
(hg18) snap-shots.  Reference genome alignment of the sequence is shown under the track 
“Your Sequence from Blat search” (in black). RefSeq gene tracks are displayed under 
“RefSeq genes” track (in blue). (A) Exon-only.  (B-C) Exon-deletion events in RefSeq 
transcripts resulting from the skipping of exonic bases and detected from the discontinuous 
blocked alignment of sequencing read. (D) Exon-skipping event. (E) Gene boundary 
expansion event at 5’UTR (alternativeTSS) (F) Gene boundary expansion event at 3’UTR 
(alternativePolyadenylation) , respectively.  (G) Internal-exon-extension. (H) Intron-
retention. (I) Intron-only.  (J) Intron-only read sequences were further used for the detection 
of potential new “intronic-exon” events that had comparable (same order of magnitude) 
expression value (estimated with as RPKM) with the expression value (RPKM) value of the 
transcript itself. 3rd intron of gene U2AF2 is shown in the figure with a potential new exon 
(pointed by blue arrow). RPKM values are displayed under the track “MAQC Human 
Reference” (in orange). (K-L) Sequencing reads that do not fall within any of the RefSeq 
transcript boundaries but map within the pre-specified gene radius (‘d’, 5kb default) are 
characterized as neighboring-exon (K) while reads that map outside gene-radius are 
characterized as gene-desert reads (L). (M) Shows an “uncharacterized” read (under “Use 
Supplied Track”) where alignment blocks of the read are separated by more than the cutoff 
value (100kb default). Such reads could not be associated or characterized with any RefSeq 
transcript and very likely be resulting from cDNA library or sequencing artifact, or 
alignment artifact. 
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and type-2), i.e., chimeras likely generated by deletions resulting from loop formation or 
other restructurings of the precursor transcript (Table 2.3). Only 13.18% of the detected 
chimeras were designated inter-genic chimeras, i.e., chimeras resulting from the potential 
fusion of heterologous gene transcripts (Table 2.3). The remainder of the aligned reads 
was comprised of “discarded” reads (38.16%, Table 2.1) and multi-hits reads (3.42%, 





In summary, the MAQC Reference Human RNA-Seq data mapped to 30,074 of 
the RefSeq transcripts (27,068 protein coding and 3,006 non-protein coding). R-SAP   
classified these detected reference transcripts as either normally or aberrantly spliced 
(Figure 2.7). 
 
Table 2.3. Number (%) of chimeric transcripts detected by R-SAP from MAQC 
Reference Human dataset and represented RefSeq transcripts 
 




Inter-chromosomal 4,327 (51.16%)  
Intra-chromosomal 4,131 (48.84%)  
 





Intragenic (type-1) 2,896 (34.24%) 1,677 
Intragenic (type-2) 524 (6.20%) 114 
Gene-desert 3,923 (46.38%) 253 
Inter-genic 1,115 (13.18%) 480 
 







R-SAP’s performance compares favorably with currently popular pipelines 
Comparison with Trans-AbySS: 
To evaluate the performance of R-SAP against existing pipelines, we compared 
R-SAP’s characterization results for the MAQC Reference Human dataset with the 
output from another commonly used pipeline, Trans-ABySS. Trans-ABySS is a highly 
respected RNA-Seq data analysis pipeline used to detect novel transcriptional events 
using the reference genome alignments of contigs obtained after performing a de novo 
assembly on short RNA-Seq reads. Since we already had 454 reads that were long 
enough to be treated as assembled contigs, we skipped the assembly step and directly ran 
the intermediate step of the Trans-ABySS that compares reference genome BLAT 
alignment of contigs (long reads) with the known transcript models. We used the 
reference genome alignment of 491,117 high-scoring reads (already classified by R-SAP, 
Table 2.1) from the MAQC test dataset and RefSeq transcripts (hg18) as reference 
transcript models. Out of 491,117 high-scoring reads, Trans-ABySS associated 127,913 
Figure 2.7. Distribution of RefSeq transcripts detected by R-SAP using MAQC 
Reference Human dataset.  “Normally spliced” RefSeq transcripts (5,039 transcripts) 
showed no novel transcriptional events. “Single novel event” transcript (15,796 RefSeq 
transcripts) and “Multiple novel event” transcripts (9,239 RefSeq transcripts) were detected 
to have only one type and more than one type of novel transcriptional event, respectively. 
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(26%) reads with known exons while R-SAP associated more than twice as many 
(299,473 or 61%, Figure 2.2 Table 2.2) high-scoring reads with known exons.  Of 
127,193 exon-associated reads, Trans-ABySS classified 4847 (0.98% of the 491,117 
high-scoring) reads as novel transcriptional events (exon-skipping, alternative splice 
sites, intron-retention, UTR expansion and new exons) (Table A.5) and the remaining 
123,066 (25.05% of the 491,117 high-scoring) reads as those mapping completely within 
the known exons.  Overall, Trans-ABySS reported a lower number of novel 
transcriptional events compared with R-SAP’s characterizations (4,847 v/s 32,194; exon-
deletion, AlternativeTSS, AlternativePolyadenylation, internal-exon-extension, multiple-
annotations; Table 2.2). The lower number of novel transcriptional events detected by 
Trans-ABySS may be due to the filtering of all the reads/contigs that have single block 
alignments with the reference genome before novel transcriptional events are detected.  
Table 2.4 displays the overlap between the characterization categories that were 
comparable between R-SAP and Trans-ABySS outputs.  R-SAP predictions included 






Comparison with Cufflinks/Cuffcompare: 
Cufflinks is a widely used ab initio assembler that reconstructs full transcript 
structures using genomic alignments of RNA-Seq fragments. Cufflinks also includes a 
module, called Cuffcompare that compares the assembled transcripts to reference or 
annotated transcripts in order to build transcript structural equivalence classes and also to 
detect novel isoforms (Trapnell et al. 2010).  In order to compare Cuffcompare 
classifications with R-SAP’s characterizations, we used our ENCODE lymphoblastoid 
cell line RNA-Seq test data from which 38,524,540 reads were aligned to the human 
reference genome (hg18) using TopHat (Trapnell et al. 2009) (see Supplementary 
Methods). Transcript assembly on the genomic alignments was performed using 
Cufflinks (see Supplementary Methods) that resulted in 76,101 transcripts of length 
varying from 73 to 38,345 bp. Assembled transcripts were reported in a GTF file that 
contains genomic coordinates of assembled transcripts and their exons. The GTF file was 
then used as the input for R-SAP and Cuffcompare. Since TopHat reports only high-
quality alignments, we considered Cufflinks assembled transcripts as high-scoring 
Table 2.4.  Comparison between R-SAP and Trans-ABySS characterization sub-
categories for the high-scoring reads from MAQC Reference Human dataset (R-
SAP characterizations include reads from “multiple-annotations” category) (Table 2 and 















Exon-skipping Exon-skipping 1419 768  757 98.56% 53.1% 
Alternative TSS  + 
PolyAdenylation 
Alternative UTR 
(5’ and 3’) 5314 357 
 
327 91.59% 5.9% 
Intron-retention Intron-retention 374 2  2 100% 0.53% 




alignments for R-SAP’s characterization module. RefSeq transcripts (hg18) were used as 
a reference annotation set for R-SAP and Cuffcompare (Table A.6 and A.7).    
Based on the classification definitions provided in Cuffcompare’s manual (see also 
(Trapnell et al. 2010)), we selected those classifications that were comparable with R-
SAP’s characterizations (comparisons are displayed in Table 2.5). Cuffcompare reported 
24,752 (32% of 76,101 assembled transcripts) as novel-isoforms while R-SAP detected 
40,025 (52.6% of 76,101) novel transcripts. 86% of Cuffcompare’s novel-isoforms were 
also reported by R-SAP as either exon-skipping (~97%), exon-deletion (~87%), internal-
exon-extension (~58%), intron-retention (~33%), alternativeTSS (~62%) or 
alternativePolyA (~57%) (Table 2.5).  While Cuffcompare reported exon-associated 
novel transcriptional events as a generic category “novel-isoform”, R-SAP provided a 
more comprehensive characterization of novel-transcriptional events. Other R-SAP 
characterization classes such as exon-only, intron-only, neighboring-exon and gene-
desert showed even higher overlap of 62%, 99.9% and 100% respectively with 
Cuffcompare’ comparable classifications  (Table A.8). 
 
 
Table 2.5. Comparison between R-SAP characterizations and Cuffcompare’s novel-
isoforms classification from transcripts assembled by Cufflinks using ENCODE 
Gm12878 cell line RNA-Seq dataset (R-SAP characterizations include reads from 





















 6961  28.12% 96.9% 





14428 58.3% 58.2% 
Intron-retention 5735  1870  7.5% 32.6% 
AlternativeTSS 6952  4292  17.5% 61.7% 












Evaluation of RNA expression level quantification 
MAQC Human Reference sample: 
Comparison between R-SAP’s RPKM values from MAQC Human Reference 
sample and gene expression values determined from Affymetrix U133 Plus2.0 resulted in  
a significant correlation (Spearman correlation = 0.67, p < 0.0001) (Figure 2.8A) that is 
in agreement with the similar correlations previously reported in (Fu et al. 2009; Griffith 
et al. 2010).  We further evaluated our expression estimates by comparing with TaqMan 
qRT-PCR measurements that is generally considered a more accurate abundance 
estimation than microarrays.  After initial filtering, we retained 962 expressed RefSeq 
transcripts from TaqMan qRT-PCR data, of which 727 were also present (RPKM > 0) in 
the RPKM estimates from R-RAP.  With TaqMan qRT-PCR estimates, we observed a 
better correlation of (Spearman correlation = 0.88, p<0.001, Figure 2.8B) of our RPKM 





Figure 2.8. Comparison of R-SAP estimated RPKM vs. Affymetrix microarray and 
TaqMan qRT-PCR expression values. A. Correlation of 0.67 (Affymetrix microarray) and 
B. 0.88 (TaqMan qRT-PCR) (B.) were obtained using the MAQC Human reference sample 
C. A higher correlation of 0.78 (Affymetrix microarray) was obtained using the Gm12878 
reference cell line from the ENCODE project. 
 42 
ENCODE lymphoblastoid cell line sample: 
To explore the possibility that expression estimates may be further improved by 
using higher throughput RNA-Seq data than are available in the MAQC Human 
Reference dataset, we used R-SAP to quantify expression levels using RNA-Seq data of a 
lymphoblastoid cell line, Gm12878, obtained from ENCODE (Birney et al. 2007) and 
compared the results with microarray data (Affymetrix Human Exon 1.0 ST arrays) 
generated from the same cell line. We mapped ~54 million sequencing tags to the 
reference human genome (alignment details are presented in Table A.9) resulting in a 
highly significant correlation (Spearman correlation = 0.77, p < 0.0001) between the 
RPKM values and the microarray generated expression values (Figure 2.8C).  
 
In order to benchmark R-SAP’s RNA expression accuracy, we further compared 
R-SAP’s RPKM values with those estimated from Cufflinks and RSEM using ENCODE 
RNA-Seq dataset.  Reference genome alignments for Cufflinks were generated using 
TopHat (mapped ~38 million reads) while reference transcript (RefSeq hg18) sequence 
alignments were generated by RSEM using BowTie (Langmead et al. 2009) (mapped ~26 
million reads). Cufflinks was run in isoform abundance estimation mode in order to 
generate FPKM values for RefSeq transcripts. Parameter setting for TopHat, Cufflinks 
and RSEM runs are describe in Supplementary Methods. RSEM generated TPM 
(transcripts per million) values as abundance measures that were further converted to 
comparable RPKM values using the conversion formula described in (Li et al. 2010a).  
 
Since expression values are observed to be robust at 1.0 RPKM for ~40 M 
mapped RNA-Seq reads (Mortazavi et al. 2008) and our ENCODE RNA-Seq dataset is 
comparable to that, we used only reference transcripts with RPKM ≥ 1 for comparing 
expression values between different methods. With Cufflinks RPKM estimates, we 
observed a high correlation of 0.84 (p<0.0001). Surprisingly, RSEM’s expression values 
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showed relatively low correlation with RPKM values from R-SAP (Spearman correlation 
0.65, p< 0.0001) and from Cufflinks (Spearman correlation 0.40, p<0.0001) (See Figure 





The low concordance of RSEM with the R-SAP and Cufflinks expression 
quantifications may be due to the fact that only uniquely mapped reads were allowed to 
be used for quantification. Also, RSEM inherently uses BowTie as an aligner and Bowtie 
is not a gapped or spliced aligner like BLAT, SSAHA2 and TopHat. Hence, reads with 
INDELs larger than few base pairs, or those resulting from novel splicing events such as 
exon-skipping or exon-extension may fail to map to the transcript sequence. Both of these 
factors may have lowered the total number of mapped reads that in-turn may affect the 
detection power and quantification accuracy of RSEM. In our ENCODE RNA-Seq 
dataset, TopHat mapped nearly 38 million reads where as RSEM mapped only ~26 
million reads.  
Figure 2.9.  Correlation plots of RefSeq transcripts (hg18) quantification estimates from 
ENCODE Gm12878 RNA-Seq data using three different methods: R-SAP, Cufflinks and 
RSEM. Log2 transformation expression estimates shown here. A Spearman correlation of A. 
0.84 (p<0.0001) and B. 0.65 (p<0.0001) was observed when R-SAP’s expression estimates 
(Y-axis) were compared with those from Cufflinks (A.) and RSEM (B.) (X-axis). C. Shows 
a correlation of .040 (p<0.0001) expression estimates from Cufflinks and RSEM. 
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Evaluation of the chimer-detection module 
In order to assess the accuracy of the chimer-detection module of R-SAP, we 
compared R-SAP’s chimeric predictions with those 206 high-confidence chimeric 
transcripts generated by ChimerDB 2.0. We observed a ~79.6% (164/206) overlap with 
the ChimerDB 2.0 predictions (Table A.2). Manual inspection indicated that the 42 
chimeric transcripts un-classified by R-SAP had multiple hits on the reference genome 
and were thus rejected as false positives by R-SAP during the filtering step in the chimer-
detection module. Although R-SAP’s filtering criteria was designed to minimize false 
positives, it should be noted that, RNA-Seq data may inherently contain some chimeric 
cDNA artifacts that are generated by template switching during reverse transcription, 
and/ or amplification and ligation reactions (Ozsolak and Milos 2011). Further 
experimental methods such as RT-PCR followed by re-sequencing should be used to 
validate the putative chimeric transcripts generated from RNA-Seq data (Guffanti et al. 
2009; Maher et al. 2009b).  
 
 
Evaluation of R-SAP’s run time performance 
We benchmarked R-SAP’s runtime performance and effect of parallelization 
against Cufflinks. For the test run purposes, we selected reference genome alignments of 
20 million reads from our ENCOE RNA-Seq test dataset that was aligned to the reference 
genome (hg18) previously using BLAT and TopHat. These 20 million reads were 
selected from high-scoring reads previously classified by R-SAP. In order to make the 
comparison between R-SAP and Cufflinks fair, we ran Cufflinks only in its quantification 
mode while R-SAP was allowed to run only characterization and transcript expression 
estimation modules.  RefSeq transcripts (hg18) were used as reference annotation set. 
Running time for R-SAP and Cufflinks with varying number of parallel threads is shown 
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in Figure 2.10. Although we observed a near linear scalability in R-SAPs performance, 




Cufflinks was implemented in C while R-SAP was implemented using Perl. It has 
been previously shown that Perl performs five to ten times slower than C (Prechelt 2000). 
Therefore, the relatively slower performance of R-SAP may be attributed to its 
implementation in Perl. Also, R-SAP was designed to generate multiple output files to 
provide detailed annotation information and data statistics. Writing multiple files 
involves extensive number of disk operations that may create high volumes of system-
overheads for large datasets and may ultimately lower the running time of the program.  
We also compared the performance of R-SAP with Trans-ABySS by comparing the time 
required to perform the characterization of high-scoring reads on MAQC RNA-Seq data. 
Figure 2.10. Benchmarking of R-SAP’s running time as compared with Cufflinks. 
R-SAP (gray line) and Cufflinks (black line) running time (Y-axis) for the quantification 
of 20 million reads from ENCODE Gm12878 RNA-Seq dataset was compared. R-SAP 
shows near linear scalability as the number of parallel threads (X-axis) are increased. 
Inset shows the same plot magnified on of Cufflinks running time. 
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Since Trans-ABySS cannot be run on multiple threads for the characterization step, we 
noted processing time on single thread only. R-SAP was observed to be almost twice as 
fast as Trans-ABySS (R-SAP: 319.29 minutes, Trans-ABySS: 728.58 minutes). Overall 
we observed that R-SAP performs slower than Cufflinks but faster than Trans-ABySS. It 
is known that the absolute running time is not an accurate measure of an algorithm’s 
performance. More accurate evaluation of the performance is only possible if other 
factors such as time and space (memory) complexity, number of instructions and 
frequency and duration of function calls are taken into consideration (Cormen et al. 2001) 
which is currently beyond the scope of this study. 
 
 
Summary and Conclusion 
R-SAP is a bioinformatics tool for the processing and analyses of the high-
throughput RNA-Seq data that integrates reference genome alignments of sequencing 
reads with known transcripts models.  
Using three publically available datasets (MAQC, ENCODE and ChimerDB 2.0) 
to evaluate different modules of the pipeline, we have shown that R-SAP can 
systematically detect novel transcriptional events including various classes of RNA 
isoforms and other transcript structures such as intra-genic  and inter-genic chimeras. R-
SAP’s performance in categorizing transcripts represents a significant improvement over 
currently available pipelines as exemplified by Trans-ABySS and 
Cufflinks/Cuffcompare. Moreover, R-SAP’s RNA expression level estimates are highly 
correlated with independent gene expression microarray analyses and experimentally 
derived qRT-PCR measurements. Currently, R-SAP simply excludes multi-hit reads from 
further analysis because they cannot be assigned to unique genomic loci.  We expect a 
significant improvement in R-SAP’s expression estimates once bias-correction and multi-
hit read re-distribution methods are included in R-SAP’s future releases. 
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R-SAP’s ability to accurately detect alternative splicing and chimeric transcripts 
is optimal for sequencing reads longer than 40-50 bp. We do not consider this to be a 
significant shortcoming given that most current and envisioned sequencing 
methodologies do or soon will generate read lengths well above this threshold (Metzker 
2010). R-SAP’s characterizations of sequencing reads are also dependent on the choice of 
the reference set of the transcripts. In our test analyses, we conservatively used RefSeq 
transcripts as our reference set. We believe that characterization can further be improved 
by using a more informative, non-redundant and inclusive set of all established transcript 
models such as UCSC, Ensembl, RefSeq and AceView (Thierry-Mieg and Thierry-Mieg 
2006; Robertson et al. 2010).  
 
One of our major goals in constructing R-SAP was to develop a pipeline that can 
be fine-tuned according to the nature of the data. We sought to achieve this goal by 
incorporating various user adjustable cutoffs in the workflow that can be used to alter the 
stringency of each analysis. For example, in case of poor quality of the reference genome 
or lower quality sequencing reads, a high rate of mismatches and small gaps can be 
compensated for by lowering the coverage, identity and/or deletion cutoff values. 
Similarly, for poorly annotated exon boundaries where alignments may extend slightly 
beyond the edge of the exon, the exon-extension, the cutoff can be increased accordingly 
to accommodate for alignment errors at exon boundaries.  
 
The characterization of transcriptomes using RNA-Seq is a multi-facited problem 
that includes cataloguing of coding and non-coding transcripts, uncovering and 
characterization of novel RNA isoforms and chimeric transcripts, detection of new splice-
sites, discovery of new transcriptional structures, measurement of RNA expression levels 
and estimation of RNA isoforms specific expression levels (Wang et al. 2009; Ozsolak 
and Milos 2011). We hope that R-SAP will prove useful as a user-friendly bioinformatics 
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tool to compliment more specialized programs in the quantitative and qualitative analysis 
of RNA-Seq data.  
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CHAPTER 3 
DE NOVO ASSEMBLY AND CHARACTERIZATION OF BREAST 
CANCER TRANSCRIPTOMES IDENTIFIES LARGE NUMBERS OF 




Gene-fusion or chimeric transcripts have been implicated in the onset and 
progression of a variety of cancers. Massively parallel RNA sequencing (RNA-Seq) of 
the cellular transcriptome is a promising approach for the identification of chimeric 
transcripts of potential functional significance. We report here the development and use 
of an integrated computational pipeline for the de novo assembly and characterization of 
chimeric transcripts in 55 primary breast cancer and normal tissue samples. De novo 
assembly allowed for the accurate detection of 1959 chimeric transcripts to nucleotide 
level resolution and facilitated detailed molecular characterization and quantitative 
analysis. A number of the chimeric transcripts are of potential functional significance 
including 79 novel fusion-protein transcripts and 80 chimeric transcripts with alterations 
in their un-translated leader regions (UTRs).  Over 300 chimeric transcripts in the cancer 
samples mapped to genomic regions devoid of any known genes.  Several ‘pro-
neoplastic’ fusions comprised of genes previously implicated in cancer are expressed at 
low levels in normal tissues but at high levels in cancer tissues. Collectively, our results 
underscore the utility of deep sequencing technologies and improved bioinformatics 
workflows to uncover novel and potentially significant chimeric transcripts in cancer and 





Gene-fusions are a prevalent class of genetic variants that have been implicated in 
the onset and progression of a variety of cancers (Mitelman 2000; Mitelman et al. 2007).  
These variants may be generated on the DNA level by genomic rearrangements [e.g., 
large deletions or insertions, inversions and/or chromosomal translocations (Maher et al. 
2009b)]. On the RNA level gene-fusion variants may be generated by co-transcription or 
transcriptional read-through of neighboring genes (Akiva et al. 2006; Parra et al. 2006), 
or by trans-splicing of multiple simultaneously processed pre-mature RNAs from 
different genes (Garcia-Blanco 2003). Recurrent gene-fusions in cancers have often been 
employed as cancer biomarkers (Mitelman 2000; Laxman et al. 2008) and, in some cases, 
as potential candidates for targeted gene therapy (Baselga et al. 1996; Druker et al. 2001).  
 In recent years, massively parallel RNA sequencing (RNA-Seq) of the cellular 
transcriptome has emerged as a promising approach for the identification of previously 
uncharacterized fusion-gene or “chimeric” transcripts of potential functional significance 
(Maher et al. 2009a; Ozsolak and Milos 2011; Wang et al. 2013). In cancer biology, for 
example, a recent RNA-Seq analysis of 24 primary breast cancer samples uncovered 15 
subtype specific fusion-genes that may serve as useful biomarkers of drug sensitivities 
(Asmann et al. 2012). In another study, analysis of 89 breast cancer and control samples 
identified several fusion transcripts involving MAST (microtubule associated serine-
threonine) kinase and Notch-family genes that may be drivers of breast cancer onset 
and/or progression (Robinson et al. 2011). 
 Currently available computational methods for fusion-gene transcript discovery 
such as Tophat-Fusion (Kim and Salzberg 2011), SnowShoeFTD (Asmann et al. 2011) 
and FusionSeq (Sboner et al. 2010), typically rely upon reference genome mapping of 
short (50 -75 bp) paired-end reads generated by the sequencing of both ends (5’- and 3’-) 
of an RNA or cDNA fragment. While these methods are relatively rapid, the results can 
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be ambiguous due to the inherent imprecision associated with genome mapping of short 
reads (Li et al. 2010a; Li et al. 2010b). In this study, we take an alternative method of 
whole transcriptome de novo assembly to screen for fusion transcripts in The Cancer 
Genome Atlas (TCGA) RNA-Seq data of 45 primary breast cancer and 10 normal breast 
tissue samples.  We developed an integrated computational workflow to generate 
significantly longer (>800 bp) contiguous sequences or “contigs”. These longer contigs 
not only provide greater accuracy in reference genome mapping but also allow for more 
reliable identification of splice-variants because longer contigs typically extend across 
multiple exons (Martin and Wang 2011). We report here the detection of 1959 chimeric 
transcripts including 1535 that are specific to the breast cancer samples, 155 that are 
present only in the normal samples and 269 that are present in both the cancer and normal 
samples. We found that a number of these fusions are of potential functional significance 
including novel fusion-proteins and chimeric transcripts with alterations in their un-
translated leader regions (UTRs).  Over 300 breast cancer chimeras mapped to genomic 
regions devoid of any known genes.  Finally, we identified several ‘pro-neoplastic’ 
chimers (Li et al. 2008) of potential significance that are suppressed in normal tissue but 
activated in cancer tissues. Collectively our findings indicate that an unexpectedly large 
number of chimeric transcripts are present in both cancerous and normal breast tissues 
and that many of these variants may play a significant role in breast cancer onset and 




For the accurate detection, characterization and quantitative analysis of chimeric 
transcripts using RNA-Seq data, we designed a computational workflow (Figure 3.1) that 
integrates several existing bioinformatics tools including our previously published 
pipeline R-SAP (Mittal and McDonald 2012). The overall workflow is as follows:  
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1. Data pre-processing: 
RNA-Seq data (see Supplemental Methods) may contain low-quality bases due to 
sequencing errors and fragments of sequencing adapters derived from failed or short 
cDNA inserts during the library preparation. Such low quality bases can reduce the 
efficiency of the assembler and lead to miss-assembly (Lindgreen 2012).  We, therefore, 
trimmed low quality bases (quality score < 20) and sequencing adapters from the 3’-end 
of the reads using ‘Trim Galore’ 
(http://www.bioinformatics.babraham.ac.uk/projects/trim galore/). Subsequently the 




Figure 3.1. Computational workflow for chimeric transcript discovery. The central 
blue block shows the workflow, orange boxes represent the tools and programs integrated 
with the workflow, purple boxes represent RNA-Seq reads and green boxes represent 
datasets from the UCSC genome database. RNA-Seq reads (in fastq format) were 
trimmed and only paired-end reads were used for the assembly process. Assembled 
contigs (in fasta format) were then aligned to the reference genome and the resulting 
alignment files (in pslx format) were analyzed by R-SAP to detect potential chimeric 
transcripts. Chimeric transcripts were further characterized by comparing alignment 
coordinates with known reference transcripts (BED format) using R-SAP. Part of the 
filtering was done by R-SAP internally while additional filtering was done using in-house 
perl scripts. A re-conformation step includes alignment of RNA-Seq reads to chimeric 
transcript sequences and also to the reference genome using Bowtie1 and Bowtie2, 
respectively.  Alignment files (in bam format) resulting from RNA-Seq reads to chimer 
transcript sequences were used to estimate the raw read-counts by expectation-
maximization using RSEM. 
 53 
2. Transcriptome assembly: 
Since, a major objective of this study was to detect chimeric transcripts where two 
non-contiguous genomic loci are involved, a reference genome guided assembly 
approach could not be used. Hence, we performed de novo assembly (assembly without 
the reference genome) using ABySS that is a memory efficient de Bruijn graph 
construction based short-read assembler (Simpson et al. 2009). The de novo assembly 
process merges short DNA or RNA sequences that share terminal overlapping bases into 
a longer contiguous sequence (contig).  The length of the terminal overlap or “k-mer 
length” is a critical parameter for assembly programs.  Unlike genomic libraries, where a 
uniform representation of each base pair can be assumed, non-normalized transcriptome 
libraries contain a broad range of expressed transcripts and splicing isoforms. Therefore, 
complete coverage of the transcriptome cannot be achieved at a single k-mer value 
assembly (Robertson et al. 2010). To maximize coverage, we adopted previous 
recommendations (Robertson et al. 2010) and varied the k-mer length from half of the 
read length up to the full read length in the increments of two base pairs at a time. For 
example, for a library with 50bp long reads, we performed assembly for k-mer length of 
25, 27, .. 49.  Multiple k-mer assemblies were then merged into a single meta-assembly 
by using the Trans-ABySS pipeline (Robertson et al. 2010) that combines overlapping 
contigs by extension and removes duplicate contigs from the assembly. 
 
3. Chimeric transcript detection and filtering: 
Assembled transcripts were aligned to the human reference genome (hg19, 
GRCh37) using BLAT (Blast like alignment tool), (Kent 2002).  Additional details are 
provided in Supplemental Methods. For potential chimeric transcript detection, we 
employed our previously developed pipeline R-SAP (Mittal and McDonald 2012) that 
efficiently detects gene-fusion events and filters potential false positives and alignment 
errors. Chimeric transcripts, representing a fusion-gene event, are very likely to produce 
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discrete alignments to distant or proximate genomic loci. These discrete alignments are 
also called as fragmented- or split-alignments. R-SAP performs the characterization of 
detected chimeric transcripts by associating the fragmented alignments with reference 
transcripts and categorizes various chimeric transcript structures according to the genic or 
inter-genic regions to which they map (Figure 3.2).  We created a comprehensive set of 
224,555 reference transcripts by merging Ensembl (Hubbard et al. 2002) and lincRNA 
(large intergenic non-coding RNAs, (Cabili et al. 2011)) annotations for hg19 available 
from the UCSC genome (Karolchik et al. 2014). These merged annotations were used as 





Figure 3.2. Chimeric transcript detection and characterization by R-SAP. 
Assembled contigs (black box) representing chimeric transcripts will produce discrete or 
fragmented alignments (blue and grey boxes) when mapped to the reference genome. It 
will result in the alignment structure where fragments of the assembled contigs will map 
to the genomic locations (e.g. chrA and chrB) underlying the fusion-gene formation. This 
structure is also called as ‘split-mapping’ of the contig. R-SAP detects split-mapping and 
then compares the alignment coordinate of each fragment with the genomic coordinates 
of the known reference transcripts (shown in green boxes). Based on the fusion-point 
mapping (vertical orange bar on the top), R-SAP can determine the transcripts regions 
(such as CDS or UTRs) are involved in the gene-fusion. 
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 Chimeric transcripts that were detected and characterized by R-SAP were 
subjected to additional stringent filtering in order to minimize potential assembly and 
alignment errors. First, to ensure the validity and significance of the alignment, chimeric 
transcript fragments were required to be at least 25 bp long and to have an alignment 
identity of >95%. Chimeric transcripts with fragments mapping to the same gene were 
discarded as potential library artifacts. Similarly, fusion-gene events between two 
paralogous genes [as determined using BioMart for Ensembl genes, see: (Flicek et al. 
2014)] were also discarded because they may potentially represent alignment errors.  
 Additional potential chimeric transcripts were discarded if either component 
fulfilled at least one of the following filtering criteria: a) Maps to mitochondrial or Y 
chromosome; b) Overlaps with genome assembly gaps or maps within 100k bps of 
centromere or telomeres (assembly gaps, centromere and telomere coordinates were 
obtained from UCSC genome database); c) Maps to genomic region containing ribosomal 
RNAs (defined by UCSC genome database); d) Has >50% overlap with the genomic low-
complexity or simple repeat regions (determined by RepeatMasker track in the UCSC 
genome table browser). 
 In order to further filter potentially miss-assembled chimeric contigs, we aligned 
the original RNA-Seq reads to the chimeric transcripts using Bowtie (Langmead et al. 
2009) in single-end mode and retained only those contigs that had support of at least two 
sequencing reads at the fusion breakpoint (Figure 3.3).  We also aligned sequencing reads 
to the reference genome using Bowtie2 (Langmead and Salzberg 2012) and defined a 
chimeric transcript to be supported by mate-pairs if both mates of the same pair map to 
the genomic locations involved in the fusion event. We required that each chimeric 




Chimeric transcripts are generally considered to be in low abundance in the 
human transcriptome (Frenkel-Morgenstern et al. 2012). Ninety-five percent (52/55) of 
our samples exceeded the sequencing depth of 100 million reads recommended for 
optimal detection of low abundance transcripts (Robertson et al. 2010). In addition, the 
correlation between the number of reads in the RNA-Seq library and the number of 
filtered chimeric transcripts was insignificant (R=0.24, p-value > 0.05) further indicating 
our estimates of chimeric transcripts are independent of depth of sequencing coverage.  
 
4. Expression quantification: 
RNA-Seq reads were mapped to the transcript sequences using Bowtie and 
abundance estimation (raw read counts for each assembled contig) was carried out using 
Figure 3.3. Re-confirmation of chimeric transcripts. In order to remove chimeric 
transcripts resulting from potential mis-assemblies, we looked for the support for 
chimeric transcripts (green-orange boxes) in the original RNA-Seq reads (black boxes). 
RNA-Seq reads were mapped to the chimeric transcripts and reads spanning the fusion-
junction (vertical red box) were counted.  Reads were also mapped to the reference 
genome and the occurrence of mate-pairs mapping to the genomic locations underlying 
the gene-fusions confirmed. We consider a chimeric transcripts as ‘confirmed’ if there are 
at least two reads supporting the fusion-junction and at least two mate pairs supporting 
the genomic alignment of the chimeric transcript. 
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RSEM ((RNA-Seq by Expectation Maximization) (Li and Dewey 2011). In order to 
compare the expression across the samples, raw read counts were normalized using the 
‘Upper Quartile’ normalization method proposed by Bullard et al (Bullard et al. 2010). 




An average of 35 chimeric transcripts per sample were detected in cancerous and 
normal breast tissue samples 
We analyzed RNA-Seq data from 45 breast adenocarcinoma primary tumors and 
10 normal breast tissue samples downloaded from the TCGA project database 
(https://tcga-data.nci.nih.gov/tcga/). The RNA-Seq data (Table B.1) were generated by 
sequencing total RNA libraries on the Illumina HiSq2000 system in paired-end mode. 
The raw data consisted of 50 bp long paired-end reads with an average of 170 million 
(from 47 million minimum to 374 million maximum; see Figure 3.4). We developed an 
integrated computational workflow that included the ABySS (Simpson et al. 2009) and 
Trans-ABySS (Robertson et al. 2010) algorithms to generate long (>800 bp) contiguous 
sequences or “contigs”. De novo assembly (see Methods) of 7.8 billion 50 bp long reads 
from the 55 RNA-Seq libraries resulted in 12.8 million contigs (an average of 233,000 
contigs per samples) with an average length of 860 bps (Table B.1).  The R-SAP 
algorithm (Mittal and McDonald 2012) was incorporated into the workflow to identify 





After subjecting the putative chimeric transcripts to a stringent set of filtering 
criteria (see Methods), 2461 high-confidence chimeric transcripts remained. Of these, 
nearly 21% were Immunoglobulin (Ig) gene fusions likely due to infiltrating T-cells in 
breast tissue and were excluded from further analysis.  After this additional filtering, 
1959 chimeric transcripts remained with an average of 35 chimeric transcripts per sample 
(3 minimum to 121 maximum) (Figure 3.5).  We compared chimeric transcripts across all 
normal and cancer samples by comparing the genomic alignment coordinates of each 
partner fragment of the chimeric transcript and allowing up to six base pairs to vary 
around the breakpoint. Out of the 1959 identified chimeric transcripts, 1535 were 
detected only in the cancer samples, 155 were detected only in the normal samples and 
269 were detected in both the normal and cancer samples (Figure. 3.6A). 
 
Figure 3.4. Sequencing coverage distribution across samples. The X-axis displays the 
55 breast tissue samples analyzed in the study and y-axis presents the number of reads in 




Figure 3.6. Distribution of chimeric and associated reference transcripts.  A) Venn 
diagram representing the distribution of chimeric transcripts in 10 normal (blue) and 45 
cancer (red) breast tissues. Two-hundred and sixty-nine chimeric transcripts were found 
in both normal and cancer samples. B) Relative distribution of protein coding (black) and 
non-protein coding (blue) reference transcripts associated with all annotated human 
transcripts vs. the relative distribution associated with chimeric transcripts detected in this 
study. Table insert displays the total numbers of transcripts in each category. 
Figure 3.5. Chimeric transcript distribution across samples before and after 
filtering. The X-axis displays the 55 breast tissue samples analyzed in this study; the y-
axis displays the number of chimeric transcripts per tissue sample. Pre-filtered chimeric 
transcripts (light blue line) are those that were detected by R-SAP while post-filtered 
chimeric transcripts (dark blue line) are those that were retained after initial filtering, re-
confirmation and removal of immunoglobulin (Ig) genes associated chimers (see 
Methods for details). 
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Chimeric transcripts were classified based on structural and functional criteria 
A detailed characterization of all chimeric transcripts identified in this study was 
carried out using the R-SAP algorithm (Mittal and McDonald 2012) and employing a 
comprehensive set of 224,555 reference transcripts (Ensembl version 73 and lncRNAs, 
see Methods). Most (98.82%) of the cancer-specific chimeric transcripts overlapped with 
at least one reference transcript. Overall 2,012 reference transcripts (corresponding to 
1,917 genes) were associated with chimeric transcripts across all breast cancer samples 
(Table B.2).  Interestingly, the proportion of protein coding reference transcripts 
associated with chimeric transcripts was significantly greater (Fisher’s exact test p < 
0.0001) than the proportion associated with the entire reference annotation set (Figure 
3.6B). This suggests that protein-coding transcripts may be preferentially selected in the 




Figure 3.7. Hierarchical classification system for chimeric transcripts. Chimeric 
transcripts are depicted as a black-grey box, reference transcripts are represented by blue 
and green boxes where thick boxes represent open-reading-frames and thin boxes 
represent 5’ and 3 UTRs. An Inter-genic chimera (A) is defined as a chimeric transcript 
where components map independently to annotated genes; A ‘gene-desert-I’ chimera 
(B) is defined as a chimeric transcript where one component maps to a gene-desert region 
(black box) while the other maps to an annotated gene  (green); A  ‘gene-desert-II’ 
chimera (C) is defined as a chimeric transcript where both components map to gene-
desert regions. A gene-desert region is defined as the genomic region devoid of any 
annotated genes within 5kb of the transcript. 
5kb 
gene-desert region 
5kb 5kb 5kb 5kb 









To more accurately characterize chimeric transcripts and infer potential functional 
significance, we first established a hierarchical classification system (Figure 3.7) where 
the chimeric transcripts were divided into three major classes: inter-genic-where the 
chimera is composed of two annotated genes; gene-desert-I where the chimera is 
composed of one annotated gene and a sequence from an un-annotated or “gene desert” 
region (lacking any annotated gene within a 5kb radius); and gene-desert-II where the 
chimera is comprised of sequences from two distant ‘gene-desert’ regions. Overall, the 
vast majority (>80%) of chimeric transcripts were inter-genic while <18% were gene-
desert-I chimers. Only ~1% of the chimers were comprised of two un-annotated 









Figure 3.8. Relative distribution of inter-genic, gene-desert-I and gene desert-II in 
(A) cancer samples, (B) in normal tissue samples, and (C) in both cancer and normal 





Figure 3.9. Structure based functional classification of chimeric transcripts. Chimeric 
transcripts are represented by black and grey boxes; reference transcripts are represented by 
blue and green boxes where thick boxes represent exons, gaps represent introns and thin 
boxes represent the 5’ and 3’ UTRs. Functional classifications are established by comparing 
the reference genome alignment coordinates of chimeric transcript regions (5’UTR, coding 
regions or 3’UTR) of the reference transcripts involved in the fusion (spanned by the 
chimeric transcript). A) Fusion-protein- Fusion of protein coding sequences from two 
different annotated genes where open-reading frames remain intact; B) 5’ UTR- Fusion of 5’ 
UTR from a gene or gene-desert region with protein coding region of another gene keeping 
the open-reading frame intact; C) 3’ UTR – Fusion of a 5’ and protein coding region of a 
gene with the 3’ UTR of another gene or gene-desert region keeping the open-reading frame 
intact; D) Cryptic splice-site- A novel splice-variant chimera where the breakpoint lies 
within a known intron. This group may include inter-genic and gene-desert-I chimeras; E) 3’ 
truncated-protein- Fusion transcript where the 5’ and coding (in frame) region of one gene is 
combined with an out-of-frame coding region of another gene or with the 3’ region of a gene 
desert region; F) Novel-RNA- Non-canonical chimeric transcript formation where the 
potential function of the transcript, if any, is unknown (e.g., 5’UTR-3’UTR fusions).  This 
group also includes out-of-frame truncated fusion-protein transcripts. 
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We further classified the detected chimeras into 5 functional sub-categories 
(Figure 3.9): A) Fusion-protein- Chimeric transcripts that combine protein coding 
sequences (CDS) from two different annotated genes while keeping the open-reading 
frames intact; B & C) 5’ or 3’ UTR- UTR exchange from another gene or gene-desert 
region in such a way that the original protein-coding region of the chimera remains intact. 
This group may include inter-genic and gene-desert-I type chimeras (Figure 3.7); D) 
Cryptic splice-site- A novel splice-variant chimera where the breakpoint lies within a 
known intron. This group may include inter-genic and gene-desert-I chimeras; E) 3’ 
truncated-protein- The in-frame coding sequence of the upstream (5’) gene in the chimera 
is partially included (truncated) while the coding region of the 3’ gene is not in frame. 
This group may include inter-genic and gene-desert-I chimeras; and F) Novel-RNA- 
Non-canonical chimeric transcript formation where the potential function of the 
transcript, if any, is unknown (e.g., 5’UTR-3’UTR fusions).  This group also includes 
out-of-frame truncated fusion-protein transcripts. The distribution of the identified cancer 
specific chimeras in each of these functional groups is displayed in Figure 3.10A, Table 
3.1; see also Tables B.3, B.4).  
 
 
Table 3.1. Distribution of breast cancer specific chimeric transcript across multiple  
structural and functional classes. 
 
 
 inter-genic gene-desert-I gene-desert-II Total 
 
fusion-protein 79 NA NA 79 
3' truncated-protein 286 133 NA 419 
5' UTR-change 41 4 NA 45 
3'UTR-change 145 21 NA 166 
cryptic splice-site 289 78 NA 367 
novel RNA 400 41 18 459 









Figure 3.10. Relative distribution of functional classes of chimeric transcripts present. A) 
only in cancer tissue samples; B) only in normal tissue samples; and C) in both normal 
and cancer samples. 
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Out of 1535 cancer specific chimers, 5% (79/1535) are fusion-proteins, 3% 
(45/1535) are 5’ UTR changes and 11% (166/1535) are 3’ UTR changes.  Cryptic splice-
site chimeras are the most abundant class of fusion transcripts (29%, 441/1535). The next 
most frequent classes were the 3’ truncated-protein (27%, 419/1535) and novel-RNAs 
(25%, 385/1535) (Figure 3.10A). These relative proportions were generally maintained in 
the normal specific and overlap class of chimeras (Figure 3.10B, C).  
 
Some fusion-protein transcripts recur across cancer patient samples 
Although the functional significance of chimeric transcripts cannot be 
unambiguously determined without experimental validation, the recurrence of chimeric 
transcripts across multiple patients is sometimes taken as tentative indication of 
biological significance (Mitelman 2000).  For example, the KRI1-ATRX chimeric 
transcript is the most frequently observed chimeric transcript in our study (present in nine 
cancer and one normal samples). It involves a fusion between a partial ORF associated 
with the KRI1 (KRI 1 homolog) gene and the DEAD helicase domain from the ATRX 
(ATP-dependent helicase ATRX) gene. The DEAD box helicases are a family of proteins 
involved in ATP hydrolysis dependent DNA and RNA unwinding that, in-turn, regulates 
RNA expression and its translational efficiency (e.g., (Tanner and Linder 2001). The 
frequency of recurrent chimeric transcripts across cancer samples is shown in Figure 3.11 




Seventy-nine cancer-specific fusions encode protein-coding domains where the 
ORFs are maintained   
We identified 79 breast cancer specific chimeric transcripts where the fusion 
occurs within the protein coding regions of the two participating genes and the open-
reading frames are maintained (Figure 3.10A; Table 3.1). We analyzed the protein coding 
domains in these 79 fusion-protein chimeric transcripts using the SMART [simple 
modular architecture research tool; (Letunic et al. 2012)] . We found that 38% (30/79) of 
the fusion-protein chimers contained functional domains for both genes involved in the 
chimera formation (Table B.6). Interestingly, 50% (15/30) of these protein coding fusion-
chimeras involved the novel joining of a signal peptide (2/15) or a trans-membrane 
domain (13/15) with a protein coding domain not previously associated with these 
functional groups.  Signal peptide sequences are components of proteins that are 
normally secreted from cells (von Heijne 1985). Trans-membrane (TM) domains are 
signaling, transport and subcellular localization components of proteins that are critical to 
a variety of inter- and intracellular interactions (Deutsch et al. 2008; Roth et al. 2008; Gui 
Figure 3.11. Recurrence of breast cancer associated chimeric transcripts across 
patient samples. Shown is the percentage of all cancer chimeric transcripts detected in 
one or more cancer patient samples. The vast majority of chimeric transcripts are specific 
to individual patients. Inset details the distribution of transcripts found in more than one 
sample. 
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and Hagenbuch 2009).  Mutations resulting in the gain or loss of TM domains are known 
to have a significant effect on cellular functions and molecular interactions (Maeda et al. 
2005). Of the 15 chimers associated with signal peptide/TM domain sequences, 12 are 
fusions with protein coding sequences (COL27A1, IGFBP4, KDM5A, MDM1, NAP1L2, 
NHP2L1, NMT2, PAXIP1, RP11-433C9.2, SMARCA4, STXBP6 and TRIO) not 















Fusions that place protein-coding genes under novel regulatory control are frequent 
in breast cancer samples 
A gene fusion between two different genes often puts one gene (downstream or 3’ 
partner gene) under the transcriptional regulatory elements (promoter or enhancer) of the 
other gene (upstream or 5’ partner gene).  Such fusion-based regulatory variants have 
often been associated with the activation of the 3’ proto-oncogene in cancer cells.  For 
example, it has been previously reported that the oncogenic transcription factor ERG 
(ETS-related gene), is up regulated in prostate cancer due to the fusion with the 5’ region 
of the TMPRSS2 (Trans-membrane protease, serine 2) gene that contains an androgen 
responsive promoter element (Tomlins et al. 2005).  
Figure 3.12. Structure of in-frame gene-fusion mutations resulting in gain of 
signaling protein domains (trans-membrane and/or signal peptide domains) 
from another participating gene. Depicted are 12 of 15 detected fusion events 
where genes were not previously associated with the signaling functions. Gene 
symbols and corresponding chromosomes (in parenthesis) are shown above of 
each gene fusion structure). Gene symbols are defined as follows:  SCNN1G: 
Sodium Channel, Non-Voltage-Gated 1, Gamma Subunit; COl27A1L: Collagen, 
Type XXVII, Alpha 1;  SLC35B1: Solute Carrier Family 35, Member B1; 
IGFBP4: Insulin-Like Growth Factor Binding Protein 4; KDM5A: Lysine (K)-
Specific Demethylase 5A; ANO2: Anoctamin 2; MDM1: Mdm1 Nuclear Protein 
Homolog (Mouse); ABCC1: ATP-Binding Cassette, Sub-Family C (CFTR/MRP), 
Member 1; IGSF3: Immunoglobulin Superfamily, Member 3; NAP1L2: 
Nucleosome Assembly Protein 1-Like 2; ANKLE2: Ankyrin Repeat And LEM 
Domain Containing 2; NHP2L1: NHP2 Non-Histone Chromosome Protein 2-Like 
1 (S. Cerevisiae); NMT2: N-Myristoyltransferase 2; ITGA8: Integrin, Alpha 8; 
PODXL2: Podocalyxin-Like 2; PAXIP1: PAX Interacting (With Transcription-
Activation Domain) Protein 1; VMP1: Vacuole Membrane Protein 1; RP11-
433C9.2: Clone based putative protien coding gene on chromosome 3; SLC24A1: 
Solute Carrier Family 24 (Sodium/Potassium/Calcium Exchanger), Member 1; 
SMARCA4: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of 
Chromatin, Subfamily A, Member 4; PTPRK: Protein Tyrosine Phosphatase, 
Receptor Type, K; STXBP6: Syntaxin Binding Protein 6 (Amisyn); TRIO: Trio 
Rho Guanine Nucleotide Exchange Factor; MARCH11: Membrane-Associated 
Ring Finger (C3HC4) 11. 
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 For the 79 fusion-protein chimeric transcripts in cancer, we estimated the fold-
change in gene expression of the 3’ partner genes involved in the fusion relative to their 
expression in their normal configurations (i.e., non-chimeric) by comparing the 
expression of each of the 3’ partners with the expression of each corresponding non-
chimeric reference transcript in a reference expression database  (see Methods).  We 
found that 24% (19/79) of the 3’ partners displayed a ≥ 2-fold expression increase in 
cancer for at least one protein coding domain (Table B.7). Several of the genes involved 
in these up-regulated fusions have been previously identified as either cancer biomarkers 
or as potential therapeutic targets.  For example, the B4GALNT2 (Beta-1,4 N-
acetylgalactosaminyltransferase 2) gene, the 3’ partner in the THRA (Thyroid Hormone 
Receptor, Alpha)-B4GALNT2 fusion, has been previously proposed as a prognostic 
biomarker of breast cancer (Patani et al. 2008) and is reported to be up regulated in 
colorectal and metastatic prostate cancer (Kudo et al. 1998; Barthel et al. 2008). The 
ABCC3 (canalicular multispecific organic anion transporter 2) gene, the 3’ partner in the 
MED1 (Mediator Complex Subunit 1)-ABCC3 fusion, is known to efflux therapeutic 
compounds resulting in multidrug resistance in cancer cells (Dean 2009; Fletcher et al. 
2010).  
 Another class of fusions that may be expected to alter patterns of gene expression 
involves the exchange of 5’ or 3’ un-translated leader regions (UTRs) of intact protein 
coding sequences. For example, alteration in the poly-A tail attached to 3’UTR and 
removal of 5’ cap (7-methyle guanosine) may promote mRNA decay and hence overall 
turnover in the cell (Mignone et al. 2002). Additionally, fusions involving the exchange 
of a 5’UTR may place a gene under the control of a novel promoter. For example, 
chromosomal rearrangements involving UTRs that result in high level expression of ETS 
(E26 transformation-specific) gene family members are common events in human 
prostate cancer (Tomlins et al. 2005).  Similarly, changes in the 3’UTR can alter 
microRNA target binding sites leading to changes in the gene expression. For example, in 
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glioblastoma, the FGFR3 (fibroblast growth factor receptor 3) gene has been shown to 
escape regulation by the miR-99a microRNA due to a fusion with the 3’UTR of the 
TACC3 (Transforming, Acidic Coiled-Coil Containing) gene (Parker et al. 2013). 
 In our analysis, 14% (211/1535) of chimeras detected in our breast cancer 
samples consisted of un-disrupted protein coding sequences fused with heterologous 
UTRs. Nearly 21% (45/211) of these are 5’UTR fusions while 79% (166/211) are fusions 
with 3’UTRs (Figure 3.10A, Table 3.1).  Most (88%, 186/211) of the UTRs were 
interchanged between two known genes but 12% of the chimers involved the UTRs of 
known coding sequences with sequences from un-annotated ‘gene-deserts’ regions of the 
genome (Table 3.1).   
 We estimated the effects of 5’ and 3’ UTR changes on gene expression by 
measuring the fold-change in the expression level of each UTR-protein coding gene 
fusion in the cancer samples relative to the protein-coding gene’s average level of 
expression in our normal samples (see Methods and Supplemental Methods).  The results 
indicate that 54 of the UTR-protein coding fusion genes are ≥ 2-fold up-regulated relative 
to their wild-type counterparts in normal cells (Figure 3.13; Table B.8). Several of the up-
regulated genes encode transcription factors previously implicated in cancer. For 
example, the epigenetic transcriptional regulator proteins CBX3 (chromobox homolog 3) 
and CBX4 (chromobox homolog 4) were up regulated in our cancer samples due to 
alternative 3’UTRs obtained by gene-fusion.  CBX3 has been previously identified as a 
potential biomarker for tumor stem cells in osteosarcoma (Saini et al. 2012), while CBX4 
has been reported to induce hypoxia-mediated activation of VEGFA (vascular endothelial 
growth factor A) and angiogenesis in hepatocellular carcinomas (Li et al. 2014). Another 
chimeric transcript up regulated in our cancer samples is a fusion of the transcriptional 
regulator-encoding gene, RARA (retinoic acid receptor, alpha), with the 3’ UTR from the 
PSME3 (proteasome activator subunit 3) gene.  Interestingly, an analogous reciprocal 
translocation between the RARA with PML (promyelocyctic leukemia) genes has been 
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previously associated with the primary cytogenetic abnormality leading to acute 
promyelocytic leukemia (Reiter et al. 2004).  
 
  
In our breast cancer samples, 17 genes were estimated to be ≥ 2-fold down-
regulated due to the fusion with novel UTRs (Table 3.1, Figure 3.13, Table B.8). For 
example, a fusion between the PTEN (phosphatase and tensin homolog) and the 3’ UTR 
of the PIK3C2A (Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 
Alpha) gene resulted in the down regulation of PTEN >2-fold in our cancer samples. 
PTEN is a well-known tumor suppressor gene that displays loss-of-function mutations in 
many cancers in (e.g., (Chen et al. 2005b).  
 Other protein coding genes involved in UTR fusions in our cancer samples that 
have been previously associated with cancer onset and/or progression are the interferon 
gamma receptor 1 (IFNGR1) gene (Duncan et al. 2007), the period circadian clock 2 
(PER2) gene (Chen et al. 2005a; Gery et al. 2007), the chloride intracellular channel 4 
(CLIC4) gene (Suh et al. 2012), the sorbin and SH3 domain containing 2 (SORBS2) gene 
(Alsafadi et al. 2011) and the eukaryotic translation initiation factor 2-alpha kinase 
encoding (EIF2AK2) gene (Vorburger et al. 2004; Lee et al. 2013).  
Figure 3.13. Gene-expression change due to fusion with heterologous UTRs. Chimera 
formation can result in the altered 5’UTR or 3’UTR while keeping the original ORF 
intact. Histograms display the number chimeric transcripts where the protein-coding 
genes are up-regulated (red) or down-regulated (green) by >2 fold in breast cancer 
samples relative to the protein-coding genes (native state) in normal breast tissue. 
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A number of chimeric transcripts include sequences from gene desert regions of the 
genome 
Previous studies have shown that the human genome is more pervasively 
transcribed than previously thought (Consortium et al. 2007). For example, the recent 
ENCODE (Encyclopedia of DNA Elements) data release suggests that nearly 80% of the 
human genome displays transcriptional functionality in a cell type specific manner (Qu 
and Fang 2013). Although many of these transcripts are derived from annotated protein-
coding genes, others may represent long non-encoding RNAs or other non-encoding 
regulatory RNAs of currently undetermined function. In our cancer samples, we 
identified 338 ‘gene-desert’ chimeras where either one (319, gene-desert-I) or both 
components (19, gene-desert-II) of the chimeric transcript maps to the ‘gene-desert’ 
regions of the genome (Figure 3.9, Table B.9).  
 We obtained transcription factor binding site (TFBS) predictions based on Chip-
Seq data from the ENCODE project [https://genome.ucsc.edu/ENCODE/; (Rosenbloom 
et al. 2013)] for five breast or mammary cell lines (HMEC, HMF, MCF-7, MCF10A-Er-
Src, T-47D).  We then searched for active TFBS in the ENCODE database at positions 
proximal to gene-desert regions involved in our chimeric transcripts. Since most TFBS 
are present within 8kb of the transcription start site of regulated genes (Koudritsky and 
Domany 2008), we considered only those TFBS mapping within 8kb of the gene desert 
transcripts (Figure 3.14A). Interestingly, all (100%, 319/319) of the gene-desert regions 
involved in chimer formation had at least one active TFBS within 8KB of the transcript. 
Also, we found that the gene-desert chimeric regions are distributed at distances form 
TFBS similar to that observed for annotated reference transcripts (Figure 3.14B). These 
findings support the contention that actively transcribed transcripts mapping to gene 
desert regions of the genome participate in chimera formation. However, since neither the 
structure nor the function of transcripts mapping to these gene-desert regions are 
currently known, the potential functional significance of gene-desert chimeras also 
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remains undetermined.  Nevertheless, the fact that 9% (28/319) of gene desert chimeric 
transcripts involve the fusion of know protein coding sequences with UTRs from gene 
desert regions suggests that at least some of these chimeras may represent significant 






Figure 3.14. Detection of transcription factor binding sites (TFBS) in proximity to 
gene-desert regions involved in chimera formation. A. A search was carried out for 
documented transcription factor binding sites (TFBS; grey box) within 8kb from gene-
desert transcripts (black box) involved in breast cancer gene fusions. B. At least one 
active TFBS is located within 8 KB of gene-desert transcripts involved in gene-fusions in 
cancer.  The distribution of the locations of TFBS from the gene-desert transcripts (red 
line) is identical to that associated with annotated reference transcripts (blue line). The x-
axis is the distance in kilobases of a TFBS detected from a transcript; the y-axis is the 









Comparative analysis of chimeric transcripts in normal and cancer samples 
identifies potential pro-neoplastic genes 
Comparison of chimeric transcripts across all normal and cancer samples was 
carried out by comparing the genomic alignment coordinates of each partner fragment of 
the chimeric transcript and allowing up to six base pairs to vary around the breakpoint. 
Although 88% (1716/1959) of all chimeric transcripts detected were found in the cancer 
samples and only 12% (243/1959) in the normal samples, this is largely attributable to the 
disproportionate number of samples examined (45 cancer vs. 10 normal).  When the 
average number of chimers detected per sample is compared, the differences are less 
dramatic (normal: 24/sample; cancer: 38/sample) albeit still significant (Student’s t-test 
p<1.05E-03). 
The unexpected abundance of chimeric transcripts in normal samples and the fact 
that the majority of these (> 60%, 269/424; see Figure 3.6) were also present in the 
cancer samples, led us to explore these chimerics in more detail. It is possible that at least 
some of the chimeric transcripts detected in normal tissue may represent “pro-neoplastic” 
fusions whose cancer causing potential is at least partially repressed in normal cells (i.e., 
oncogene expression repressed; tumor suppressor potential amplified). For example, 
chimeric transcripts of the well-studied chronic myeloid leukemia causing BCR-ABL 
fusion gene have been detected at low levels in the blood cells of healthy individuals as 
well (Boquett et al. 2013).  Similarly, the anti-apoptotic chimeric transcript comprised of 
the zinc finger genes JAZF1 (JAZF zinc finger 1) and JJAZ1 (also known as SUZ12 or 
SUZ12 polycomb repressive complex 2) is highly expressed in nearly 50% of all 
endometrial stromal sarcomas (Koontz et al. 2001; Hrzenjak et al. 2005), but has also 
been detected at low levels in normal endometrial stromal cells as well (Li et al. 2008). 
We detected 269 chimeric transcripts that were shared between our normal and 
breast cancer samples. Of these, 4 were identified as in frame fusion-protein coding 
transcripts of potential pro-neoplastic significance (ZBTB47-FGD1, KRI1-ATRX, 
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CACNA1D-CTNNBL1, and SCAF4-TNRC6A) (Figure 3.15, Table B.10). RNA-Seq reads 
were mapped to the assembled contigs representing each of these 4 chimeras and read 
counts were estimated using RSEM (RNA-Seq by Expectation Maximization) (Li and 
Dewey 2011) and normalized using upper-quartile normalization (Bullard et al. 2010) 
(see Methods). Two of the chimeras (ZBTB47-FGD1 and KRI1-ATRX) displayed a >2.5-
fold increase in expression in cancer relative to the normal samples (Figure 3.15A & B; 
Table B.10). A third chimera (SCAF4-TNRC6A) displayed a 1.3-fold increase in 
expression in the cancer samples while a fourth fusion (CACNA1D-CTNNBL1) displayed 
a decrease in expression in the cancer samples (Figure 3.15 C, D; Table B.10).  
In the ZBTB47-FGD1 chimeric transcript, a BTB/POZ domain (BR-C, ttk and bab 
domain/Pox virus and Zinc finger virus and zinc finger domain) from ZBTB47 (Zinc 
Finger And BTB Domain Containing 47) is fused with the RhoGEF (a.k.a., the Dbl 
homologous domain), PH (pleckstrin homology) and FYVE domains from FGD1. 
Interestingly, a previously identified oncogenic fusion gene (Dbl) was also found to 
contain a RhoGEF domain whose over-expression is essential to the Dbl gene’s 
oncogenic potential (Cerione and Zheng 1996). Over expression of FGD1 has also been 
previously associated with cancer progression in prostate and breast cancer (Ayala et al. 
2009). The 3’ member of the KRI1-ATRX fusion (ATRX) has been previously associated 
with childhood neuroblastoma (Cheung et al. 2012) and the 3’ member of the CACNA1D-
CTNNBL1 fusion (CTNNBL1), is associated with an anti-apoptotic, tumor suppressive 
function (Suzuki et al. 1997; Jabbour et al. 2003) consistent with its reduced expression 









Figure 3.15. Potential pro-neoplastic gene-fusions that are functionally suppressed 
in normal breast tissues but activated in cancer tissues. Shown is the structure of four 
gene-fusions and associated protein domains that we have characterized as potential pro-
neoplastic fusions. Square boxes with numbers represent exons (5’ gene: orange, 3’ gene: 
blue); exons not shown in the figure are represented by a dashed empty box; the red star 
represents the fusion point for each chimera; gene symbols and (chromosomal location), 
as well as, the number of each fusion transcript detected in normal (N) and cancer (C) 
samples is presented above each gene-fusion structure. Protein domains are displayed 
under each structure. Histograms on the right display average expression levels of the 3’ 
members of the fusions in their native or parental (pre-fusion) genes in normal samples 
(blue) and the expression of the fusion transcript in cancer samples (orange) bar. Fold 
change is shown under each expression plot. All of the 3’ partners of these fusion 
transcripts have been previously associated with cancer progression (see text for details). 
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Discussion 
The oncogenic potential of gene fusions and fusion transcripts was first 
recognized in malignant hematological disorders and childhood sarcomas (Mitelman et 
al. 2004). In recent years, the importance of fusions in the onset and progression of a vast 
diversity of solid tumors has become more widely appreciated. The rapidly growing 
awareness of the extensiveness and potential importance of fusion transcripts in cancer 
has been facilitated by the high-throughput transcriptome sequencing of a broad spectrum 
of cancer types. The Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/) currently 
lists well over 1800 fusions identified in > 63,000 cancer patient samples and it has been 
estimated that gene-fusions account for > 20% of human cancer morbidity (Mitelman et 
al. 2007). 
 We present here an integrated computational workflow that not only allows 
accurate detection of chimeric transcripts to nucleotide level resolution but also facilitates 
detailed molecular characterization and quantitative analysis. We employed this 
workflow to analyze 55 breast transcriptomes that, to our knowledge, is the first such 
study to explore global patterns and characteristics of chimeric transcripts in any tumor 
using a de novo assembly approach.  
 Since the de novo assembly approach allows for construction of long contigs 
capable of traversing multiple exons, we were able to map each known gene associated 
chimer to a specific splice-variant. Accurate mapping followed by hierarchical structural 
and functional classification enabled us to systematically infer the potential functional 
role and biological significance of a number of novel chimeric transcripts. While prior 
RNA-Seq based studies have focused primarily on the canonical gene fusion structures of 
fusion-protein and UTR associated alterations, our de novo assembly based approach 
allowed us to explore other classes of fusion structures such as cryptic-splice sites and 
non-canonical RNA structures. Although, the potential functional impact of many of 
these atypical structures has yet to be determined, their widespread occurrence in our 
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breast cancer samples strongly suggests that this class of chimeric transcripts warrants 
further investigation. In total, we identified 105 novel gene-fusions, 13 of which were 
detected across multiple patient samples.  
 Most previously identified gene-fusions in cancer have been associated with 
oncogene activation (Kumar-Sinha et al. 2006). Our findings suggest that gene-fusions 
can also result in significant down regulation of potentially significant genes. For 
example, while we identified 54 examples of genes being up regulated in cancer due to 
fusions with heterologous UTRs, an additional 17 such fusions resulted in a significant 
down regulation in gene expression including the well-known tumor suppressor gene 
PTEN. 
 Chimeric transcripts are typically associated with cancer cells but their presence 
in normal somatic cells is often overlooked. In our study, we identified a number of 
fusion transcripts that are present in both normal and cancer tissues but significantly 
differentially expressed in these two tissue types.  Several of these were identified as 
potential pro-neoplastic fusions where domains previously associated with oncogenic 
functions were up regulated in cancer while those previously associated with tumor 
suppressor functions were down regulated in cancer.  
 Finally, we detected a large number of chimeric transcripts mapping partially or 
completely to genomic regions devoid of any known genes (“gene deserts”). We observe 
that the fusion transcripts involving gene-desert regions can result in the fusion of altered 
5’ or 3’ UTRs to known protein-coding genes resulting in significant changes in gene 
expression. We also detected the fusion of transcripts mapping to two distinct gene-desert 
regions giving rise to novel RNA structures of currently unknown significance. 
 Overall, our de novo assembly approach has revealed an unexpected prevalence 
and diversity of chimeric transcripts in breast cancer tissues and underscores the utility of 
deep sequencing technologies and improved bioinformatics workflows to uncover novel 
and potentially significant chimeric transcripts in cancer and normal somatic tissues.  
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IDENTIFICATION AND EXPRESSION ANALYSIS OF GENE 
FUSIONS AND OTHER STRUCTURAL VARIANTS IN 




Genomic rearrangements or structural variants (SVs) are one of the most common 
classes of mutations in cancer. We report here the results of an integrated DNA 
sequencing and transcriptional profiling (RNA sequence and microarray gene expression 
data) analysis of six ovarian cancer patient samples.  Matched sets of control (whole 
blood) samples from these same patients were used to distinguish cancer SVs of germline 
origin from those arising somatically in the cancer cell lineage. We detected 10,034 
ovarian cancer SVs (5518 germline derived; 4516 somatically derived) at base-pair level 
resolution. Only 11% of these variants were shown to have the potential to form gene-
fusions and, of these, less than 20% were detected at the transcriptional level. 
Collectively, our findings indicate that although gene fusions and other SVs may be 
important factors in the onset and progression of ovarian cancer, it may not simply be the 
occurrence of these variants but their regulation that ultimately determines their 




Cancer genomes are characterized by the presence of several classes of somatic 
mutations including point mutations, copy number alterations and chromosomal 
rearrangements or structural variants (SVs) (Lupski and Stankiewicz 2005; Pleasance et 
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al. 2010). Of these, SVs are the most frequent (Futreal et al. 2004; Stratton et al. 2009; 
Edwards 2010) and include tandem-duplications, inversions, deletions, insertions and 
inter-chromosomal translocations (Lupski and Stankiewicz 2005). Although cancer 
genomes may harbor hundreds to thousands of SVs, only a handful are considered of 
potential functional significance, typically involving protein-coding genes (Korbel et al. 
2007; Stephens et al. 2009; Hillmer et al. 2011). Functionally significant SVs often 
involve gene-fusions that place protein coding genes under novel regulatory controls 
and/or result in the generation of novel fusion proteins (Rabbitts 1994; Rowley 2001; 
Mitelman et al. 2007). A well-known example is the reciprocal translocation between 
chromosome 9 and 22 resulting in expression of the BCR-ABL fusion protein in chronic 
myeloid leukemia (Nowell 1962; Rowley 1973; Lugo et al. 1990).  
Advances in the application of the paired-end (or mate-pair) approach to high-throughput 
sequencing has made genome-wide surveys of genomic rearrangements possible (Korbel 
et al. 2007; Bashir et al. 2008; Campbell et al. 2008; Medvedev et al. 2009; Murphy et al. 
2012) and recent studies have uncovered a number of new gene fusions and other SVs of 
potential functional significance in a variety of cancer genomes (Stephens et al. 2009; 
Quinlan et al. 2010; Hillmer et al. 2011; Jiao et al. 2011; Malhotra et al. 2013). However, 
the potential importance of gene-fusions and other SVs to cancer onset and progression 
would be compromised if these variants were not expressed. Indeed, recent studies have 
revealed that “normal” tissues can harbor transcriptionally repressed “pro-neoplastic” 
SVs that only become oncogenic when transcriptionally activated (Li et al. 2008).  Thus, 
to fully evaluate the functional significance of gene fusions and other SVs in cancers, 
DNA sequence analyses should ideally be coupled with transcriptional profiling. In an 
effort to address this issue in ovarian cancer, we utilized an integrated computational 
workflow to analyze DNA sequencing and transcriptional profiling (RNA sequence and 
microarray gene expression data) data from six ovarian cancer patient samples. In 
addition, DNA sequence data from matched sets of control (whole blood) samples from 
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these patients were used to distinguish cancer SVs of germline origin from those arising 
somatically in the cancer cell lineage. We report here the detection of 10,034 ovarian 
cancer SVs (5518 germline derived; 4516 somatically derived) at base-pair level 
resolution. Only 11% of these variants were shown to have the potential to form gene-
fusions and, of these, less than 20% were detected at the transcriptional level. 
Collectively, our results demonstrate the presence of large numbers of germline and 
somatically derived gene-fusions and other SVs in ovarian cancer tissues and underline 




Materials and Methods 
Sequencing data acquisition 
Whole genome sequencing (WGS) data for  six ovarian serous 
cystadenocarcinoma and matched somatic control (whole blood) samples were selected 
from ‘The Cancer Genome Atlas’ (TCGA, http://cancergenome.nih.gov/) data portal 
(https://tcga-data.nci.nih.gov/tcga/) using dbGAP in BAM file format (see Supplementary 
Methods for more details). 
 
WGS data consisted of a total of nearly 22 billion (minimum 1.3 billion – 
maximum 2.54 billion per sample) 75 - 100 bp long paired-end (in forward-reverse 
orientation) reads generated from Illumina GAII instrument.  RNA-Seq data consisted of 
a total of nearly one billion (minimum 105 million - maximum 243 million per sample) 
75 bp long paired-end reads generated from Illumina GA II system. Selected samples and 
sequencing data is summarized in Table C.1. 
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BAM files containing sequencing data were sorted using Picard tools’ SortSam 
and converted to FastQ format using BamToFastQ program 
(http://genome.sph.umich.edu/wiki/BamUtil). 
 
Genomic SV Detection using WGS 
Massive amount of whole genome sequencing data presents a challenge in 
detecting complex structural variants with high-accuracy. In order to accurately detect 
and characterize genomic structural variants, we designed a streamlined workflow 




Figure 4.1.  Integrative data analysis workflow for structural variants. The upper 
workflow summarizes detection and validation of SVs using whole genome sequence 
data. The bottom left workflow summarizes the detection of fusion-transcripts using 
RNA-Seq data. The estimation of differential gene-expression using microarray data is 
summarized in the bottom right of the figure.  
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The workflow for the WGS data is described as follows: 
SV detection: 
Overall quality of the WGS reads were assessed using FastQ.  Low quality (Q < 
20) bases and adapter sequences were removed from the ends of the reads. The remaining 
reads were aligned to the human reference genome hg19 (GRCh37 assembly, UCSC 
genome database) using Bowtie2 (Langmead and Salzberg 2012). Unmapped reads were 
stored in a separate file. PCR duplicates were removed from the alignment files using 
Picard tools’ MarkDuplicate program. Since the highly repetitive/low complexity 
genomic regions may result in ambiguous or low confidence alignments, we filtered out 
all alignments with mapping quality (MAPQ) < 35. Various classes of large structural 
variants (SVs) were detected using SVDetect (Zeitouni et al. 2010). The SVDetect 
algorithm searches for clusters of paired-ends reads creating distinct signatures of 
structural variants in the alignment file. SV signatures are called if anyone or both of the 
inherent characteristic of paired-end sequencing constraints (i.e., library insert-size, 
alignment orientation of mates relative to each other) are violated. Based on the clusters 
of paired-end signatures, the SVs calls are generated and the location of breakpoints is 
estimated.  Genomic loci involved in a SV (a.k.a.“links”) are required to be supported by 
a minimum number of paired-end reads as determined by the sequencing depth of 
coverage (Korbel et al. 2009). Since our samples have different sequencing depths of 
coverage, different cutoff values were determined for each sample (summarized in Table 
C.2).   
 
Filtering: 
We observed that more than 50% of the SV calls were ‘small_duplications’ that 
could be the result of artifacts generated during the library preparation. Thus, we 
conservatively removed such calls as well those described as ‘co-amplicons’ and 
‘undefined’ calls generate from ambiguous paired-end signatures. We further removed all 
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the SV calls that had more than 50% overlap with the low-complexity genomic regions. 
Since, reference human genome quality is questionable around the centromere and 
telomere regions and near the assembly gaps, we also removed SVs mapping within 100 
kilo base-pairs of these  regions. Finally, we also removed called SVs that mapped either 
to mitochondrial or Y chromosome or currently un-localized regions of the genome 
(“Un”, “hap”, etc.). 
 
Targeted assembly of SVs: 
The paired-end read approach for SV detection does not provide base-pair level 
breakpoint information but rather provides genomic regions that may contain potential 
breakpoints. Also, short (75 – 100bp) read mapping to the reference genome may 
generate false clusters of paired-end reads resulting in false SV calls.  In order to confirm 
SV calls generated by SVDetect and to detect the breakpoint at the base-pair resolution, 
we performed a targeted de novo assembly for each SV call. De novo assembly is 
performed by progressively merging redundant DNA sequences with shared overlapping 
ends determined by a pre-specified parameter called ‘k-mer’ length. The goal is to 
reconstruct the exact DNA sequence underlying the SV.  For the assembly of each SV 
call, we included sequencing reads mapping within the 500 bps on either side of the 
genomic regions involved in an SV call. Also included are reads that initially could not 
be mapped to the reference genome. Since a complete assembly cannot be achieved using 
single k-mer length, we performed multiple k-mer length assemblies by varying k-mer 
from half of the read length (37 to 50 bp) to the complete read length (75 to 100 bps) in 2 
bp increments. Multiple k-mer assemblies were performed using ABySS (Simpson et al. 
2009) and later merged using Trans-ABySS (Robertson et al. 2010) that also removes 
redundant assembled sequences from the assembly. In order to further expand the 
assembly set, we performed multiple k-mer assemblies using an additional assembly 
program, Velvet (Zerbino and Birney 2008). 
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Validation and breakpoint detection: 
Assembled DNA sequences (also called as contigs) were mapped to the human 
reference genome (hg19) using the BWA (Li and Durbin 2010) program that can 
independently align parts (also known as fragments) of a DNA sequence to discrete 
genomic loci.  Such mapping is called split-mapping (Figure 4.2). Genomic coordinates 
of the paired-end based SV calls from SVDetect were compared with the fragmented 
alignments of the assembled contigs and breakpoints were determine for SV calls 
supported by the assembly.  For each SV, two breakpoints are detected each 
corresponding to the genomic locus participating in the SV formation. Validation and 
breakpoint detection was carried out by using our previously developed pipeline, R-SAP 
(RNA-Seq analysis pipeline) (Mittal and McDonald 2012), that accurately detects 
fragmented alignments (split-mapping) representing potential gene-fusions and/or 
genomic rearrangements.  R-SAP modules were slightly modified to include intragenic 
SVs such as deletions and insertions and other complex SV signatures such as 
transpositions that were not detected in the original R-SAP configuration. In order to 
minimize false SV calls supported by the assembly, the assembled contigs were aligned 
to the reference human genome using an additional alignment algorithm SSAHA2 (Ning 
et al. 2001), and the SVs again validated again using R-SAP. In this way, we with a 






Fusion transcript detection using RNA-Seq 
RNA-Seq reads obtained from TCGA were initially subjected to quality and 
adapter filtering using FastQC and TrimGalore. Reads were then aligned to the reference 
human genome in paired-end mode using TopHat using the ‘fusion-search’ mode. 
TopHat-fusion (Kim and Salzberg 2011) searches for potential breakpoints using the 
‘split-read’ alignment of sequencing reads that are also supported by additional ‘paired-
end’ reads. Potential fusions reported by TopHat were further evaluated using the 
reference transcript annotations that we defined as the merged set of Ensembl (version 
73) and lncRNAs available from UCSC genome database(Hubbard et al. 2002; Karolchik 
et al. 2004; Cabili et al. 2011). We further required that each fusion be supported by at 
least one split-read and one paired-end read alignment. We conservatively discarded 
fusions where both ends of the fusion were confined to a single gene loci. 
 
 
Figure 4.2. Validation and breakpoint detection.  Assembly of a SV call representing a 
translocation event between two chromosomes (green and orange) is illustrated. SV calls 
are generated by SVDetect using paired-end signatures (blue and purple boxes represent 
paired-mates). Reads mapping to the genomic regions surrounding them  (black boxes) 
are assembled using de novo assembly that also included initially unmapped reads. 
Assembled contigs shown here as a black line represent the DNA sequence underlying 
the translocation event. Contigs are mapped back to the reference genome and if split-
mapping is observed, a SV call is considered validated and breakpoints (shown in red)  
are considered detected. 
chrA chrB 
de novo assembly 
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We downloaded gene-expression microarray data for the ovarian cancer samples 
using TCGA data portal. Due to the unavailability gene expression data from of our 
matched normal or control set, we utilized as a control microarray data form eight 
samples collected from healthy ovarian tissue from independent patients (described in 
Table C.3).  
The microarray expression data was generated by RNA hybridization to the 
Affymetrix HT_HG-U133A gene chips and data files were provided in ‘cel’ format.  
Expression values were estimated and normalized by the RMA normalization method 
from the cel files using Affymetirx Expression Consol.  For each gene, average 
expression across all of the eight normal samples and the average value is used as the 




DNA sequence analyses 
More than 10,000 structural variants (SVs) identified in six ovarian cancer patient 
samples  
DNA sequencing data of matched sets of six ovarian serous cystadenocarcinoma 
and six somatic control (whole blood) tissues were downloaded from the ‘The Cancer 
Genome Atlas’ (TCGA, http://cancergenome.nih.gov/) data portal (https://tcga-
data.nci.nih.gov/tcga/) using dbGAP in BAM file format. The raw data consisted of 22 
billion 75-100 bp paired-end reads (minimum 1.3 billion – maximum 2.54 billion per 
sample; Table C.1). An integrated computational workflow was developed to facilitate 
the data analysis (Figure 4.1, see Methods for details). 
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Initial alignments resulted in the mapping of 84% of the DNA-Seq reads to the 
human reference genome. A subsequent series of stringent filtering and validation steps 
(see Methods) resulted in a total of 35,721 SV calls.  To confirm these SVs and to 
determine breakpoints at base-pair level resolution, targeted de novo assembly was 
performed for each SV call (Figure 4.2). After correcting for multiplicity of confirmed 
SVs (presence of the same SV across multiple samples), a total of 14,719 unique SVs 
were detected across all samples (Table C.4).  Of these, 32% (4,685) were uniquely 
present in the somatic control (blood) samples, 31% (4,516) were uniquely present in the 
cancer samples and 37% (5518) were present in both the control and the cancer samples 
(Figure 4.3, Figure 4.4).  We classified those SVs detected in both the cancer and somatic 
control samples as germline derived cancer variants since the presence of precisely the 
same SV in divergent somatic cell types implies a common clonal (germline) origin. 
Those SVs detected exclusively in the cancer samples were classified as somatically 
derived cancer variants arising in the cancer cell lineage. Of the 10,034 SVs detected in 




Figure 4.3. Comparison between germline and cancer SVs. Circles represent the total 
number of SVs detected in somatic control (whole blood) (blue circle) and cancer (red 
circle) tissue samples collected from six ovarian cancer patients. SVs corresponding to 













The SVs were comprised of seven structural classes: inversions, transpositions, 
tandem-duplications (100 bps - 10 million bps in size), deletions (>20 bps), insertions 
(>20 bps), inverted-duplications and translocations.  The distribution of these SVs across 
all samples is summarized in Figure 4.5. The most frequent class of SVs were deletions 
and germline derived deletions were >2X more frequent than somatically derived 
deletions. Germline and somatically derived inversions and transpositions were present in 
approximately equal frequencies while somatically derived SVs were more frequent than 
Figure 4.4. Comparison between germline and cancer SVs for individual patient 
samples. Circles represent the total number of SVs detected in somatic control (whole 
blood) (blue circle) and cancer (red circle) tissue samples collected from each of 6 
ovarian cancer patients. SVs corresponding to the overlap region identifies germline 
derived SVs while non-overlapping cancer SVs are somatically derived. 
P1 
31% 26% 43% 
P2 
36% 38% 26% 
P3 
31% 40% 29% 
P4 
33% 40% 27% 
P5 
38% 33% 29% 
P6 
18% 41% 41% 
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germline derived variants for all other classes of SVs (insertions, inverted-duplications, 





Analysis of the frequency of recurrence of SVs across samples indicates that 
germline derived SVs have the highest rate of multiplicity (Figure 4.6). Nearly 55% of 
germline derived SVs are present in multiple patient samples reflecting naturally 
occurring variation in the human population. In contrast, only 6% of the somatically 





Figure 4.5. Distribution of SVs across structural categories.  Somatically derived (red) 
and germline derived (green) SVs were further categorized according to the underlying 
genomic rearrangement. Deletions were the most abundant category accounting for the 
majority (~71%) of the germline derived SVs. Corresponding data is shown in the table 






Ovarian Cancer SVs can be divided into 3 groups based upon the location of 
chromosomal breakpoints 
Detected SVs were annotated using a combined set of 224,555 normal reference 
transcripts (Ensembl annotations, release 73 and lncRNAs from the UCSC genome 
database). We classified SVs detected in our cancer samples into three groups based on 
the location of breakpoints relative to the reference transcripts as follows: inter-genic SVs 
are defined as variants with breakpoints mapping to two or more annotated genes located 
at distant genomic locations; intra-genic SVs are variants with breakpoints mapping 
Figure 4.6. Multiplicity of SVs across 
samples. X-axis represents multiplicity 
(number of occurrences) of somatically 
derived (shown in red bars) and germline 
derived (shown in green bars) SVs across 
cancer samples. Y-axis represents 
percentage of SVs present in a particular 
multiplicity. Table at the bottom contains 
data corresponding to the figure. 
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within a single annotated gene; and gene-desert SVs are variants with breakpoints 
mapping to distant locations within genomic regions devoid of annotated genes (“gene 
deserts”) (Figure 4.7).  Intra-genic SVs are the most abundant class (50%, 5,031/10,034) 
followed by gene-desert (39%, 3,942/10,034) and Inter-genic (11%, 1,061/10,034) SVs 
(Figure 4.8, Figure 4.9A). Inter-genic SVs are >2X more abundant among somatically 
derived variants than among germline derived variants (677 vs. 384, Figure 4.9B) while 
the number of intra-genic (2,151 vs. 2,880) and gene-desert SVs (1,688 vs. 2,254) are 
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Gene-desert C. 
Figure 4.7. Structural classification scheme for SVs. SVs are depicted by black-grey 
boxes, reference transcripts are represented by the blue and green boxes. Thick boxes 
represent open-reading-frame or coding sequences (CDS) while thin boxes represent 
5’UTR ( on the left)  and 3’UTR ( on the right). 
Inter-genic SVs (A) – breakpoints map to annotated genes located at distant genomic 
locations; intra-genic SVs (B)- breakpoints map within the same gene; gene desert (C)- 






Figure 4.8. Characterization of SVs. Genomic coordinates of SVs and their breakpoint 
were compared with the reference transcripts that served as the basis of hierarchical 
classification into functionally relevant classes. The total number of SVs in each class is 
shown in black font while the numbers in parenthesis represent the distribution of  
somatically derived (red) and germline derived (green) SVs. 
Figure 4.9. Distribution SVs across functional characterization classes. A.  
Distribution of total detected SVs among functional classes. B.  Distribution of inter-
genic SVs between somatically derived and germline derived SVs. Inter-genic SVs are 








Inter-genic SVs encompass multiple classes of fusion-genes   
We further divided inter-genic SVs based on the location of breakpoints within 
the various gene regions, i.e., the promoter region (defined as breakpoint regions within 5 
kb up-steam of the transcriptional start site), the 5’ and 3’ untranslated leader regions 
(UTRs), and the protein coding sequence (CDS) (Table C.5). Inter-genic SVs where the 
5’- partner gene sequence is fused with either a non-protein coding gene (e.g., lncRNA) 
or with an unannotated region of the genome (gene-desert) are classified as 5’ truncated 
SVs. Finally, inter-genic variants that do not manifest canonical gene structures (5’UTR-
promoter-CDS-3’UTR), display gene components in incorrect orientation (e.g., 5’ UTR-
CDS-promoter-3’UTR, gene desert-3’ CDS, etc.) or otherwise cannot be functionally 
evaluated are classified as uncharacterized RNA (Table C.5).  
 
The relative distribution of these sub-classes of inter-genic SVs in the cancer 
samples is shown in (Figure 4.10A). The most abundant (37%, 398/1061) sub-class of 
inter-genic variants is associated with alterations in the promoter region of genes. These 
altered promoter variants along with the less frequent alternative 5’ UTR (4%, 45/1061) 
and 3’ UTR (7%, 74/1061) sub-classes all have the potential to alter the expression of 
associated genes without altering coding sequences. Inter-genic SVs associated with the 
coding regions of genes also have the potential to alter the expression levels (e.g., the 5’ 
partner gene typically provides the promoter region in addition to 5’ coding sequences 
while the 3’ partner may bring novel microRNA binding sites in its 3’ UTR) but may also 
generate novel fusion proteins if reading frames are maintained. While only 5% 
(20/1061) of the inter-genic SVs involve the fusion of coding regions of different genes, 
38% (20/52) of these variants were in frame. Interestingly, the vast majority of the in-
frame gene fusions (85%, 17/20) were somatically rather than germline derived 
suggesting that these de novo SVs have either been selectively favored in the cancer cell 
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lineages or selected against in germline lineages or both. The majority of the coding 
region inter-gene fusions (62%, 32/52) were out-of-frame.  
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Figure 4.10. Distribution SVs across 
functional characterization classes. A.  
Inter-genic SVs (germline and somatically 






The breakpoints of most intra-genic SVs map to introns 
The Intra-genic class of SVs was sub-divided into those with breakpoints 
mapping completely within the same intron (intronic) and those where at least one 
breakpoint mapped to an exon (exonic) . The vast majority of intra-genomic SVs (94%, 
4,744/5,031) were intronic (Figure 4.10B, Table C.6). Although intronic variants may 
affect splicing functions, they do not affect coding regions per se. Only 6% (287/5,031) 
of the intra-genic SVs grouped into the exonic sub-class.  The majority of these exonic 
variants (138/287 or 48%) mapped to non-protein coding genes (e.g., lncRNAs) and are 
thus of currently undefined significance. The breakpoints of the remaining exonic 
variants mapped predominantly within 5’ or 3’ UTRs (5’UTRs: 17/287 or 6%; 3’UTRs: 
64/287 or 22%). These intra-genic variants could potentially alter regulatory sequences 
involved in gene expression (e.g., upstream regulatory sequences in 5’UTRs or 
microRNA binding sites in 3’UTRs).  The breakpoint of 24 % (68/287) of the exonic 
variants mapped to coding regions (CDS), which are  presumed to disrupt the ORF and 
are labeled “disruptive” (Table C.6). 
 
Many of the SVs map to gene desert regions 
Although nearly 39% (3,942/10,034) of the detected SVs were classified as gene-
desert variants (Figure 4.8, 4.9A), their potential functional significance cannot be 
reliably inferred since the structure of transcriptional units within gene-desert regions is 
currently unknown. 
 
Gene expression analyses 
A minority of gene fusions is transcribed 
Inter-genic SVs have the potential to generate gene-fusions. Thus, in an effort to 
explore the extent to which this class of potential gene fusions were being expressed in 
our cancer samples, we downloaded from the TCGA data portal the results of RNA 
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sequencing (RNA seq) and microarray (Affymetrix) profiling studies carried out on these 
same samples. The raw RNA-seq data consisted of 1 billion 75 bp paired-end reads 
(minimum 105 million - maximum 243 million per sample) (Table C.1). These data were 
again analyzed using the computational workflow outlined in Figure 4.1 (see Methods for 
details).  
 
Since inter-genic SVs with breakpoints mapping to the promoter region 
(398/1061) cannot be qualitatively distinguished using the RNA seq data, they were 
excluded from the RNA seq analysis but are included in the microarray expression 
analysis described below. All other classes of inter-genic SVs/gene fusions (coding 
region, 5’ truncated, alternative 5’ UTR, alternative 3’ UTR and uncharacterized RNAs) 
were included in the RNA seq analysis. The breakpoints of these gene fusion transcripts 
were detected in the RNA-Seq data using split-read mapping (see Methods). Since 
introns are spliced out during mRNA processing and absent in the RNA-Seq data, we 
adjusted intronic SV breakpoints to the closest exon included in the gene fusion. SVs 
were categorized as “detected” by RNA seq if transcripts were found in at least one of the 
6 cancer samples examined. Based on this criterion, 16% (103/663) of these potential 
gene fusions were found to be expressed in the cancer samples. The percentage of the 
transcribed germline derived fusions (19%, 30/158) was slightly higher than the 
somatically derived fusions (15%, 73/505) (Table C.1, Table C.7).  
 
Only somatically derived coding sequence gene fusions are expressed  
All 8 coding-gene fusions detected at the transcript level were somatically 
derived. Six of these fusions were in frame. In-frame fusions typically result in novel-
fusion proteins that bring different protein domains together. We analyzed the 
rearrangement of protein domains resulting from the 6 in-frame gene fusions using 
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SMART database (http://smart.embl-heidelberg.de/) (Letunic et al. 2012). The fusion-
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Two of the six in-frame gene fusions, FARP1-SLC15A1 (13q32.2 inversion) and 
RP1-27O5.3–ZNF643 1p34.2 - 1p35.1 deletion 1p34.2 - 1p35.1 deletion), resulted in a 
novel juxtaposition of protein-coding domains. The domains associated with the FARP1-
SLC15A1 fusions are involved in a variety of signal transduction pathways that have 
previously been shown to influence cell-cell adhesion, cell migration and morphogenesis 
(Clucas and Valderrama 2014). Similarly, the BTB/POZ domain (Broad-Complex, 
Tramtrack and Bric a brac) contained within the region of the RP1-2705.3 gene involved 
in the RP1-27O5.3–ZNF643 fusion has been previously implicated in ovarian cancer 
growth and recurrence (Nakayama et al. 2006). The potential functional significance of 
the remaining 4 somatically derived coding region gene fusions is currently unknown 
1-2 2-3 
DNAJB1  (chr 19) MED26  (chr 19) 










Figure 4.11.  Structure of the six transcribed SVs resulting in in-frame gene-
fusions. Figure represents the structure of the gene-fusion and associated protein 
domains. Square boxes with numbers represent exons (5’ partner gene: blue, 3’ partner 
gene: orange), red lines represent the fusion breakpoint, gene symbols corresponding 
chromosomes (in parenthesis) are shown on top of each gene fusion structure). 
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(Figure 4.11). Other classes of transcribed inter-genic SVs include alternative 5’ UTRs 
(4%, 2/45), alternative 3’ UTRs (9%, 7/74), 5’-truncated (19%, 39/208), and 
uncharacterized RNAs (17%, 47/284) (Table 4.1, Table C.7).  
 
a Overlap between RNA-Seq  and microarray detection 
 
     




     
5'-truncated 167 29 NA 29 
coding-gene-fusion 45 8 NA 8 
Uncharacterized RNA 216 33 NA 33 
alternative 5'UTR 30 1 7 8 
alternative 3'UTR 47 2 14 16 
Promoters 172 NA 21 21 
     
Total 677   115 
     
     




     
5'-truncated 41 10 NA 10 
coding-gene-fusion 7 0 NA 0 
Uncharacterized 
RNA 68 14 NA 14 
alternative 5'UTR 15 1 5 5a 
alternative 3'UTR 27 5 4 8a 
Promoters 226 NA 16 16 
     
Total 384   53 
     
 
Table 4.1.  Summary of the number of the various types of SVs detected in the DNA 
sequencing analysis and their expression as detected by RNA seq or microarray 
studies (see text for details). 
A. Somatically derived 
B. Germline derived 
 109 
Microarray analysis 
Inter-genic SVs with breakpoints mapping within the promoter region or within 
the 5’ or 3’ UTRs leave coding regions unchanged but may be expected to alter patterns 
of gene expression. In order to search for possible quantitative changes in expression 
associated with these inter-genic SVs, we utilized the results of gene-expression 
microarray analyses downloaded from the TCGA data portal for the same six ovarian 
cancer patient samples (Note that the 5’-truncated, coding-region and uncharacterized 
RNA fusions are not distinguishable in microarray studies and thus were analyzed 
exclusively in the RNA seq analyses discussed above). Since gene expression profiles of 
normal ovarian tissue from these patient samples were not available, for controls, we 
downloaded and utilized the results of gene expression microarray profiles of normal 
ovarian tissue from 8 other age-matched women (Table C.3). Expression values were 
computed and normalized using the RMA normalization of the cel file data using the 
Affymetirx Expression Consol.  Fold-change in expression relative to the average of the 
eight normal samples was computed for each of the genes associated with inter-genic 
altered promoters, as well as altered 5’ and 3‘ UTRs SVs (Table 4.1, Table C.7).  
 
Of the 517 (249 somatically derived and 268 germline derived) gene-fusions 
(promoter, alternative 5’UTR and alternative 3’ UTR only) analyzed, 13% (42 
somatically derived + 25 germline derived)/517) were differentially expressed (Table 4.1) 
including 37 that were up-regulated and 49 that were down-regulated relative to controls 
(Table C.7).     
 
Chromosomal translocations are most frequently associated with changes in gene 
expression 
Chromosomal translocations are the physical basis of gene fusions and, as shown 
in Figure 4.12, they are also the most frequent class of variants associated with significant 
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changes in gene expression both for somatically derived (61/122 or 50%) and germline 
derived SVs (30/65 or 46%). Although only 6% ((573 + 232)/ (4516 + 5518), Figure 4.5) 
of all SVs are associated with translocations, our transcriptional analysis indicates that 
they are the most likely class of SVs to be associated with changes in gene expression 
(Figure 4.12, Table 4.2, Table C.8).  
 
 
Table 4.2. Summary of the number of various functional classes of SVs across 











Figure 4.12. Genomic distribution of inter-genic SVs. A. displays the distribution of 
somatically derived inter-genic SVs, B. displays the distribution of those somatically 
derived inter-genic SVs that were either transcribed (detected using RNA-Seq) or resulted 
in differential gene-expression (measured using gene-expression microarrays). Similar 
distributions for germline derived SVs are shown in C and D. Each line (blue: 
translocation, red: deletion, green: tandem-duplication, yellow: inverted-duplication, 
orange: inversion, grey: insertion, dark grey: transposition) connecting two different 
chromosomes (outer circle) represents inter-chromosomal and straight lines restricted to a 




In this study, we followed an integrated high-throughput computational workflow 
to accurately detect a remarkably large number (10,034) of SVs in cancerous tissue 
samples isolated from 6 ovarian cancer patients.  This value is considerably larger than 
previous estimates of the number of SVs in other types of cancer tissues and cell lines 
(e.g., (Hillmer et al. 2011) possibly due to the greater accuracy afforded by our de novo 
assembly approach and/or because of  the exceptional chromosomal instability known to 
be associated with ovarian cancers (Wang et al. 2012).   
The majority (5518) of our identified SVs were determined to be of germline 
origin, apparently reflective of the abundance of naturally occurring SVs believed to be 
segregating in human populations (Conrad et al. 2010).  An additional large number of 
the SVs (4516) identified in the ovarian cancer samples were determined to be of somatic 
origin arising de novo in the cancer cell lineage.  Somatically derived SVs have recently 
been reported to constitute a major fraction of somatic tissue genetic variation in humans 
(O'Huallachain et al. 2012) and our findings are consistent with these reports.   
While a major fraction of the SVs identified in our study were shown to map to 
un-annotated regions of the genome (gene deserts), the functional significance of these 
variants is currently unknown.  In contrast, inter-genic SVs, while constituting only 11% 
of the SVs identified in our study, are the basis of gene-fusions- a well defined class of 
SVs demonstrated to be of functional significance in the onset and progression of a 
variety of cancers (Korbel et al. 2007; Stephens et al. 2009; Hillmer et al. 2011).   
To our knowledge, ours is the first study to analyze both the presence and 
expression of SVs in the same panel of ovarian cancer patient samples. Among the most 
notable findings coming out of this comparative analysis is the remarkably low 
proportion of cancer SVs that are being transcribed. Only 20% of the gene fusions 
detected in our DNA seq analysis were detectable in the RNA seq analysis of the same 
samples. Remarkably, none of the germline derived gene fusions but all of the 
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somatically derived gene fusions were detectable on the RNA level. This observation 
suggests the existence of a regulatory mechanism or mechanisms that can effectively 
suppress those older more established SVs segregating in natural populations, but that is 
(are) lost or otherwise rendered ineffective in suppressing de novo variants arising in 
cancer cell lineages.  Consistent with this possibility is the recent finding that a 
microRNA (miR-203) that targets and suppresses expression of the BCR-ABL fusion 
protein is hypermethylated in several hematopoietic tumors including chronic 
myelogenous leukemias and some lymphoblastic leukemias. Re-expression of this 
microRNA has been shown to significantly reduce BCR-ABL fusion protein levels and to 
coincidently inhibit tumor cell proliferation (Bueno et al. 2008).  The relevance of such 
regulatory mechanisms to the fact that several gene fusions previously identified as 
biomarkers of cancer have recently been found to be present in normal healthy 
individuals (Nambiar and Raghavan 2013) remains to be determined.   
Further evidence of the importance of the regulation of gene fusions and other SVs in 
cancer comes from our microarray analyses. We found that 10-30% of both germline and 
somatically derived fusions display a significant change in the expression of those genes 
involved in the fusion relative to normal controls.  In several cases, changes in the 
expression of the protein coding domains involved in the fusions have been previously 
associated with cancer onset or progression.  
Collectively, our findings are consistent with other recent studies indicating that 
gene fusions and other SVs may be more important factors in the onset and progression 
of cancer than previously envisioned (Robinson et al. 2011) . Our results further indicate, 
however, that it may not simply be the occurrence of these variants in cancers but their 
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In this dissertation work one of the most common mutations in cancer, gene-
fusions, and their global patterns in breast and ovarian cancer was studied by using high-
throughput DNA sequencing technologies. Chapter 2 describes the bioinformatics 
pipeline called R-SAP that we developed and implemented to systematically analyze and 
characterize cancer transcriptomes. In Chapter 3, R-SAP is integrated with additional, 
more specialized tools, to study gene-fusions in 55 breast cancer and healthy 
transcriptomes using RNA-Seq data. Overall a de novo assembly approach uncovered 
novel and potentially functional chimeric transcripts and revealed an unexpected 
prevalence and diversity of chimera in breast cancer tissues. In Chapter 4, gene-fusions 
are studied at the genome level using whole genome sequencing (WGS) data from 
ovarian cancer and matched somatic control samples.  This study provides insight into the 
structure of genomic rearrangements underlying the gene-fusion structures observed in 
the cancer transcriptome.  Further integration of RNA-Seq and WGS data analyses 
reveals the transcriptional consequences of germline and cancer specific structural 
variants. 
Gene-fusion or chimeric transcripts that originate as a result of genomic 
rearrangements have been implicated in the onset and progression of a variety of cancers 
(Futreal et al. 2004; Lupski and Stankiewicz 2005; Mitelman et al. 2007). Recurrent 
gene-fusions that are also causally implicated in cancer are considered as potential 
biomarkers and therapeutic targets (Mitelman 2000; Laxman et al. 2008). Recent 
advancements in massively parallel RNA sequencing (or ‘RNA-Seq’) of the cellular 
transcriptome is a promising approach for the identification and characterization of 
fusion-gene transcripts (Maher et al. 2009a; Metzker 2010). Massive amounts of 
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sequencing data generated from the complex cellular transcriptome poses bioinformatics 
challenges that require highly specialized tools (Wang et al. 2013).  
CHAPTER 2 presents our R-SAP program, a high-performance and highly-
customizable user friendly bioinformatics pipeline for the analysis of RNA-Seq data.  A 
built in multi-threading capability allows R-SAP to attain a near linear scalability in 
computation time while analyzing high-volumes of sequencing data. One of the 
characteristic features of the pipeline is its ability to accurately detect and annotate 
chimeric transcripts for their functional inference using a hierarchical characterization 
and classification system. R-SAP’s applicability is demonstrated (CHAPTER 2) using 
MAQC human reference RNA-Seq data (Mane et al. 2009). Validation of the chimer-
detection module shows 80% sensitivity using a curated set of 206 chimers from 
ChimerDB2.0 (Kim et al. 2010). The remaining 20% of reads were filtered out by R-SAP 
as ‘ambiguous’ fusions since they were originating from the repetitive regions of the 
genome.  
In order for R-SAP to accommodate short (< 150 bp) sequencing reads such as 
those generated from Illumina and IonTorrent sequencing systems, we configured it to 
work with transcriptome assemblers such as Cufflinks, Scripture and Trans-ABySS. This 
compatibility is achieved by making use of the standard file formats such as GTF (Gene 
Transfer Format) or and BED (Browser Extensible Data) that are standard output from 
currently used assembly programs. We demonstrate the applicability of R-SAP to 
transcriptome assembly in CHAPTER 3 and further expand its applicability to whole 
genome sequence data analysis in CHAPTER 4. 
While prior RNA-Seq studies have primarily focused on the canonical gene 
fusion structures of fusion-protein and promoter associated transcriptional deregulation, 
global patterns of chimers in cancer had yet to be explored. CHAPTER 3 presents the 
development and use of an integrated computational pipeline for the de novo assembly 
and comprehensive characterization of chimeric transcripts in 55 primary breast cancer 
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and normal tissue samples. De novo assembly resulted in longer contigs that not only 
provided greater accuracy in reference genome mapping but also allowed for more 
reliable identification of splice-variants because longer contigs typically extend across 
multiple exons. The integrated workflow developed in CHAPTER 3 demonstrates that 
specialized bioinformatics tools can complement each other and work synergistically. For 
example, although R-SAP has inherent filters to exclude ambiguous chimers, it cannot 
filter out the miss-assembled transcripts. But with a reconfirmation step using Bowtie and 
original RNA-Seq reads, we were able to significantly reduce R-SAP’s false positive 
calls.  By following a hierarchical functional classification, we were able to uncover a 
variety of fusion structure classes such as cryptic-splice sites and non-canonical RNA 
structures. Although, their functional consequences cannot be determine currently, their 
widespread presence is intriguing enough for further investigation.  
Comparative analysis of chimeric transcripts between normal (or control) and 
cancer samples resulted in 269 shared chimeras. The presence of chimeric transcripts in 
normal samples is typically overlooked but their differential expression in cancer cells 
relative to the normal tissue is indicative of their ‘pro-neoplastic’ potential (Li et al. 
2008). In CHAPTER 3, we identified four potential ‘pro-neoplastic’ fusions that involved 
protein-domains previously implicated in cancer. Such chimeric transcripts are potential 
candidates for use as biomarkers for early diagnosis.. 
Recent studies (Consortium et al. 2007; Qu and Fang 2013) have shown that 
transcription is not limited to genes. Previously considered ‘gene-desert’ regions can be 
transcribed in a highly cell type specific manner (Cabili et al. 2011; Prensner et al. 2011). 
In our study, we found that gene-desert regions can also participate in chimera formation 




Gene-fusions predominantly result from genomic-rearrangements that are also 
known as structural variants (SVs). CHAPTER 4 presents the study of SVs in ovarian 
cancer using high-throughput whole genome sequencing data. Breakpoints associated 
with SVs were detected at the nucleotide level resolution by implementing an integrated 
computational workflow that also incorporates R-SAP (CHAPTER 2). Systematic and 
hierarchical characterization of SVs using the known gene-model revealed several non-
canonical gene-fusion structures that were also observed in the breast cancer 
transcriptome (CHAPTER 3). The results provide evidence of the genomic origin of the 
diverse gene-fusion structures.  Our analysis of genomic rearrangements in ovarian 
cancer also confirms our previous observation (CHAPTER 3) of participation of gene-
desert regions in creating gene-fusion structures that can lead to transcriptional 
deregulation. 
SVs are mainly associated with cancer but in our study we also observed SVs in 
the germline samples. We evaluated the differences in the functional significance 
between germline-derived and cancer specific (somatically derived) SVs at the 
transcriptional level using RNA-Seq and gene-expression microarray. Interestingly, 
somatically derived SVs are more likely to result in gene-fusion chimeric transcripts and 
also result in transcriptional deregulation as compared with the germline-derived SVs. 
For example, transcription of in-frame coding gene-fusions was detected only for 
somatically-derived cancer specific SVs and none for germline-derived SVs. Also, 
somatically derived SVs resulted in significantly higher numbers of transcriptionally 
deregulated genes than germline-derived SVs (CHAPTER 4). We suspected that the 
differences in functional consequences of SVs could be attributable to the differences in 
the structure of the underlying genomic rearrangements. We observed that the majority of 
the germline SVs were simple deletions, while somatically derived SVs were enriched for 
more complex genomic rearrangements such as translocations and tandem-duplications.  
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Overall we observed that out of all the detected SVs, only 11% result in potential 
gene-fusion structures and out of these, only 20% were detected at the transcriptional 
level.  Additionally, only somatically derived in-frame coding-gene fusions are expressed 
(CHAPTER 4).  Collectively, our results demonstrate the presence of large numbers of 
germline and somatically derived gene-fusions and other SVs in ovarian cancer tissues 









Description of pipeline parameters that are adjusted in order to change the 
stringency during the pipeline run 
 Percent identity cutoff:  Minimum percent identity to call an alignment hit as 
high-scoring (default value is 95%). This cutoff is also the minimum identity required by 
each alignment pair in the chimeric transcript detection step. 
 Percent coverage cutoff: Minimum alignment query coverage to call an alignment 
as high-scoring (default value is 90%). 
 Deletion cutoff: Minimum number of skipped exonic bases from the reference 
genome due to the gapped alignment of query read before the read is characterized as 
exon-deletion (default value is 10 bp). 
 Exon extension cutoff: Minimum number of extended bases outside the exon 
boundaries to characterize it as internal-exon-extension (if extension is in intron) or 
alternativeTSS or alternativePolyadenylation (if the extension is out of the transcriptional 
boundaries) (default value is two bp). 
 Gene radius: Maximum extension of the known transcript in the upstream or 
downstream region to include intergeninc region mapped reads in the known gene models 
(default value is 5000 bp). This value can be set to zero if all the intergenic mapped reads 
need to be characterized as gene-desert. 
 Gap tolerance: Maximum number of bases required on the query read before it is 
designated as chimeric transcript and searched for the alignment pair (default value is 20 
bp). This cutoff is also the maximum allowed query bases between the fragmented 
alignments of the query sequence. 
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 Annotation mode:  Two possible values; “unique”, “multi”.  “Unique” is the 
default setting that will cause the pipeline to characterize each high-scoring read to only 
one best fitting known transcript. If set as “multi”, reads will be characterized with all the 
known transcripts the read mapped to. 
 
Obtaining data from ChimerDB 2.0 
ChimerDB 2.0 (http://ercsb.ewha.ac.kr:8080/FusionGen) (Kim et al. 2010) is a 
database of chimeric transcripts (or fusion gene transcripts) that are detected from the 
publicly available nucleotide sequences available in databases such as GenBank and SRA 
(short read archive). It also reports gene fusion pairs that are previously reported in 
literature. We downloaded GenBank accession IDs and corresponding fusion gene pairs 
for the chimeric transcripts present in ChimerDB 2.0. Downloaded fusion gene pairs were 
cross-referenced against the fusion gene pairs that were reported in literature and also 
available at Chimer DB 2.0. We retained only those GenBank accession IDs that had 
fusion gene pairs that were also reported previously in the literature. Nucleotide 
sequences for the retained GenBank accession IDs were obtained using nucleotide 
database (http://www.ncbi.nlm.nih.gov/nuccore) at NCBI. The resulting 206 sequences 
were defined as high-confidence dataset of chimeric transcripts that were used as the test 
data for testing the chimer detection module in R-SAP. 
 
Raw RNA-Seq data cleaning 
454 sequencing reads for MAQC Reference Human dataset were masked for low-
complexity repeats (including simple repeats) using DustMakser (Morgulis et al. 2006) 
program before aligning them to the reference genome. Masked regions were trimmed 
using in-house perl scripts. Trimmed reads shorter than 20bp were excluded because of 
the BLAT’s (Kent 2002) limitation to align such sort reads with high accuracy. 
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Alignment screening and top-scoring hit selection 
Command line BLAT (downloaded from http://users.soe.ucsc.edu/~kent/src/) 
generated psl and pslx output files don’t have alignment percent identity, percent query 
sequence coverage and alignment score. These values were necessary for each alignment 
hit in order to sort and prioritize all possible reference genome hits for each sequencing 
read. 
For alignment score and alignment percent identity calculations, we incorporated 
the code available at http://www.genome.ucsc.edu/FAQ/FAQblat.html#blat4  in our 
alignment-screening module. 
 
Percent query coverage was calculated as:   
((alignment end position in query- alignment start position in query)/(query length)) X 
100 
In order to obtain the best possible alignment (top-hit), all the alignment hits were 
sorted hierarchically first on alignment score, then on percent query coverage (if scores of 
the two alignment hits were equal) and finally on percent alignment identity (if coverage 
were equal). 
 
Gene expression microarray data analysis 
Cel files from Affymetrix Human U133Plus2.0 and Affymetrix Human Exon 1.0 
ST V2 obtained from GEO (Gene Expression Omnibus at: 
http://www.ncbi.nlm.nih.gov/geo/) were analyzed using Affymetrix Expression Consol 
1.1 provided on Affymetrix website www.affymetrix.com. Samples were RMA 
normalized, and transcript/gene level expression analysis and probe-set annotation was 




TaqMan qRT-PCR data analysis 
Four replicates of TaqMan qRT-PCR measurements for MAQC Human 
Reference sample were obtained from GEO. Original dataset consisted of normalized 
expression values and their presence/absence calls for 1044 probes.  Expression value for 
each probe was taken as the mean expression values across the four replicates. A probe 
was considered expressed if it had at least 75% presence call (present call in at least three 
replicates). 973 expressed probes were retained after the filtering. Expressed probes were 
then assigned to RefSeq transcripts (hg18) using TaqMan probe annotations provided 
under GEO’s platform record for TaqMan (platform: GPL4097). 962 probes were 
successfully assigned to RefSeq transcripts and 727 of them were also detected (R-SAP 
RPKM > 0) in MAQC Human Reference RNA-Seq data. 
 
ENCODE Gm12878 cell line RNA-Seq data analyses 
Running TopHat: 
TopHat v1.3.1 (Trapnell et al. 2009) (available at http://tophat.cbcb.umd.edu/) 
was used for the human reference genome (hg18) alignment of ENCODE Gm12878 
RNA-Seq reads. TopHat was run as: 
 
tophat -m 1 -F 0 -g 1 --coverage-search <bowtie_index> <input_fastq_file>  
 
Using “–g 1” parameter, we allowed only uniquely mapped reads to be reported 
by TopHat. Overall 38,524,540 (out of 87,929,372) reads were mapped to the reference 
genome. TopHat outputs alignments in bam format that is used as input for Cufflinks 
(Trapnell et al. 2010). 
Running Cufflinks: 
a. Assembly mode: 
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Aligned reads from TopHat were assembled using Cufflinks v1.1.0 (available at 
http://cufflinks.cbcb.umd.edu/). Cufflinks was run as: 
 
cufflinks -u -F 0.0 <tophat-alignments> 
 
Transcriptome assembly resulted in 76,101 assembled transcripts. Cufflinks assembled 
transcripts are reported in GTF format that contains genomic coordinates of transcript an 
putative exons. 
 
a. Abundance quantification mode: 
In order to estimate the expression values of RefSeq (hg18) transcripts, we ran Cufflinks 
v1.1.0 in its quantification mode. Aligned reads from TopHat and RefSeq transcripts in 
GTF format were used as input for Cufflinks. Cufflinks was run as: 
cufflinks -G Hg18RefSeq.gtf -u -F 0.0 --overhang-tolerance 3 <tophat-alignments> 
 
Parameter “--overhang-tolerance 3” was used to match R-SAP’s default cutoff for “exon-
extension” (3 bp). Cufflinks reports abundance estimates as FPKM (fragments per 
kilobase of transcript per million fragments mapped) that are comparable to RPKM 




Cufflinks assembled transcripts (from previous step) were compared with RefSeq 
(hg18) transcripts using Cuffcompare. Cuffcompare is a module in Cufflinks program 
that compares multiple transcript sets (including reference transcripts) in order to 
generate transcript structural variant classifications. Cuffcompare was run as: 
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cuffcompare -r Hg18RefSeq.gtf -R  -C <cufflinks-transcript-assembly> 
 
Running RSEM: 
RSEM v1.1.13 (Li and Dewey 2011) (available at 
http://deweylab.biostat.wisc.edu/rsem/) estimates transcript expression values by aligning 
RNA-Seq reads to reference transcript sequences. RSEM uses BowTie as an aligner that 
is run inherently from RSEM. In order to run RSEM, we supplied original fastq files for 
the Gm12878 RNA-Seq data and RefSeq (hg18) transcript sequences that were obtained 
using UCSC Table browser (http://genome.ucsc.edu/cgi-bin/hgTables). 
RSEM was run in two steps: 
 
1. Preparing reference transcript sequence index: 
rsem-prepare-reference <bowtie-path> <Hg18RefSeq.fa> 
 
2. Estimating expression: 
rsem-calculate-expression --out-bam --seed-length 28 <bowtie-path> --bowtie-n 3 --
bowtie-e 200 --bowtie-m 1 --phred33-quals  
--fragment-length-mean 200 --fragment-length-sd 80 <input-fastq-file> <reference-
transcript-sequence-index> 
 
Cufflinks default values for fragment length distribution mean and standard deviation 
were used for RSEM run. RSEM estimated 
RSEM reports two measures of abundance estimates: Expected read count from each 
transcript and  estimated fraction of transcripts  made up by a given isoform or gene (τ 
value). τ value is generally converted to TPM (transcripts per million)  by multiplying by 
106 in order to get the expression value of transcripts. TPM value is not directly 
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comparable to RPKM or FPKM value. We converted TPM values to comparable RPKM 
values using the conversion formula provided in (Li and Dewey 2011): 
RPKMi = (10
9x τi)/(∑j τilj) 
Here i corresponds to the ith RefSeq transcript and j varies from 1 to total number of 









































Table A.1. Data sources and types of datasets that were used for the demonstration 
of R-SAP’s application as well as its performance assessment and testing. 
 
 


















































































































Table A.2. GenBank accession IDs for the 206 EST and mRNA sequences that were 
used as the high confidence test dataset for testing the chimer-detection module of 
R-SAP. 164 (~80% of 206) Accession IDs (in red color) were reported as chimer-
transcripts by R-SAP. 
 
AB000268.1 AF492832.1 AY624559.1 EU446645.1 AB300355.1 
AB001342.1 AJ131466.1 AY624560.1 FM165197.1 AB300356.1 
AB038155.1 AJ131467.1 AY633656.1 FM165198.1 AB300357.1 
AB274722.1 AJ251843.1 AY803272.1 L03357.1 AF047022.1 
AB275889.1 AJ251844.1 BC008826.1 L22179.1 AF125093.1 
AF024541.1 AJ251845.1 D90075.1 M13096.1 AF143407.1 
AF031404.1 AJ295163.1 DQ084494.1 M19730.1 AF186109.1 
AF041811.2 AJ297349.1 DQ204770.1 M25946.1 AF230662.1 
AF060927.1 AJ298917.1 DQ204771.1 M30829.1 AF231996.1 
AF060928.1 AJ299261.1 DQ204772.1 M30832.1 AF254086.1 
AF060929.1 AJ299262.1 DQ204773.2 M31213.1 AF272376.1 
AF060930.1 AJ301611.1 DQ437654.1 M73779.1 AF295356.1 
AF060931.1 AJ301612.1 DQ437655.1 S50916.1 AF297746.1 
AF102845.1 AJ303089.1 DQ451148.1 S72478.1 AF297747.1 
AF113911.1 AJ417079.1 DQ831522.1 S72604.1 AF310722.1 
AF123094.1 AJ438986.1 DQ841178.1 S75763.1 AF390893.1 
AF125808.1 AJ549094.1 DQ845345.1 S77574.1 AF524261.1 
AF125809.1 AJ549095.1 DQ845346.1 U02308.1 AF533988.1 
AF177236.1 AJ549096.1 DQ886024.1 U02368.1 AY186998.1 
AF177237.1 AJ972402.1 DQ898313.1 U41814.1 AY380223.1 
AF177238.1 AM491359.1 DQ898314.1 X03541.1 AY380226.1 
AF177239.1 AM491360.1 DQ912588.1 X06418.1 D45915.1 
AF186110.1 AM491361.1 DQ912589.1 X62947.1 EU327511.1 
AF231995.1 AM491362.1 DQ912590.1 X98708.1 FM165196.1 
AF254087.1 AM491363.1 EF051633.1 X98709.1 M82827.1 
AF254088.1 AY040324.1 EF158045.1 X98710.1 S71225.1 
AF272374.1 AY040555.1 EF374064.1 Y08643.1 S72479.1 
AF272375.1 AY043457.1 EF406122.1 Y15913.1 S72621.1 
AF272383.1 AY138857.1 EF423615.1 Y15914.1 S72865.1 
AF272384.1 AY138858.1 EF525170.1 Y15915.1 S74529.1 
AF272385.1 AY138859.1 EF632110.1 Y15916.1 S79325.1 
AF297748.1 AY138860.1 EU090248.1 Y15917.1 S79332.1 
AF297749.1 AY186997.1 EU090249.1 Y15918.1 S81242.1 
AF364037.1 AY187920.1 EU216064.1 Y15919.1 U35622.2 
AF373587.1 AY187921.1 EU216066.1 Y15920.1 U41743.1 
AF395885.1 AY187922.1 EU216070.1 Y15921.1 X07537.1 
AF422798.1 AY380222.1 EU216071.1 Y16346.1 X79200.1 
AF477006.1 AY380224.1 EU236680.1 Z35761.1 X85960.1 
AF487522.1 AY380225.1 EU236948.1 AB000267.1  
AF487905.1 AY624556.1 EU314929.1 AB001343.1  
AF487906.1 AY624557.1 EU364772.1 AB012575.1  




Table A.3. Intron-retention events detected in MAQC Reference Human dataset 













Table A.4. Distribution of “multiple-annotations” reads that were detected in 
MAQC Reference Human dataset using R-SAP. Since more than one type of novel 
transcriptional event was detected in each of the “multiple-annotations” reads, reads 
representing characterization sub-categories here may be overlapping. “Exon-skipping” 
and “intron-retention” events are already included in “exon-deletion” and “internal-exon-






























Reads (Represented  
RefSeq transcripts)  
 
Internal-exon-extension 18,419 (7,648) 
Complete intron-retention 361 (275) 
 
Total number of retained introns 305 
 
 
Total Multiple-annotations 3020 
 










Table A.5. Distribution of Trans-ABySS characterized reads that were also 
classified as “high-scoring” by R-SAP previously using MAQC Human Reference 
RNA-Seq data. RefSeq transcripts (hg18) were used as annotated set of transcripts. 
“novel-transcript” are those that could not be mapped to any of the known RefSeq exon 
by Trans-ABySS. Novel transcriptional event sub-categories  (AS3, AS, AS53, 
novel_exon, novel_intron, novel_utr, retained_intron and skipped_exon) have 121 
overlapping reads between them. Filtered-out reads are those that were not reported in 




(characterization)   
Reads (% total  
“high-scoring”) 
Associated RefSeq  
transcripts 
 
AS3 1447 (0.29%) 960 
AS5 1503 (0.30%) 1031 
AS53 24 (0.004%) 22 
novel_exon 608 (0.12%) 462 
novel_intron 259 (0.05%) 212 
novel_utr 357 (0.072%) 190 
retained_intron 2 (0.0004%) 1 
skipped_exon 768 (0.15%) 568 
 
Total novel-transcriptional 
events (121 overlapping 
subtracted from the total sum) 
4847(0.98%) 2548 
 
 Mapping within known exons 123066 (25.05%) 16211 
 
Total exon-associated 127913 (26.04%) 18759 
 
Novel-transcripts 144173 (29.35%) NA 
 
Total reported 272086 (55.4%) 18759 
Filtered-out 219031 (44.6%)  
 




















Table A.6. Distribution of transcripts that were assembled from ENCODE 
Gm12878 RNA-Seq data using Cufflinks and then characterized by R-SAP. RefSeq 





(characterization)   
Reads  (% Cufflinks assembled 
transcripts) 
Represented RefSeq  
transcripts 
 
Exon-skipping 1,389 (1.82%) 1,186 
Exon-deletion 597 (0.78%) 548 
AlternativeTSS 1,957 (2.57%) 4,382 
Alternative Polyadenylation 2,848 (3.74%) 5,361 
Internal-exon-extension 15,416 (20.25%) 6,744 






14,255 (18.73%) 7,667 
 
Total novel-transcripts 40,025 (52.59%) 13,638 
 
Exon-only 8,940 (11.74%) 8,275 
Intron-only 10,172 (13.36%) 3,772 
Neighboring-exons 3,166 (4.16%) 2,282 
Gene-desert 8.582 (11.27%)  
Uncharacterized   5,216 (6.85%)  
 

























Table A.7. Distribution of transcripts that were assembled from ENCODE 
Gm12878 RNA-Seq data using Cufflinks and then classified by Cuffcompare into 












Potential novel-isoform j 24,752 (32.52%) 9240 
Full match + contained =, c 14,015 (18.41%) 11046 
Falling entirely within 
intron 
i 10,149 (13.33%) 3765 
Possible polymerase 
run (2kb away from 
reference transcript) 
p 1,772 (2.32%) 1361 
Unknown, intergenic u 10,131 (13.31%) 0 
Generic reference exon 
overlap 
o 1,389 (1.82%) 1257 
Exonic overlap (on 
opposite strand) 
x 765 (1%) 586 
Intron overlap ( on 
opposite strand) 
s 306 (0.4%) 297 
Single exon with partial 
intron overlap (pre-
mRNA fragment) 











Table A.8. Comparison between R-SAP’s characterizations and Cuffcompare’s 
classification of transcripts that were previously assembled from ENCODE 
Gm12878 RNA-Seq dataset using Cufflinks (also see Table 5 and Supplementary 










R-SAP Cuffcompare  #Reads %Cuffcompare %R-SAP  
 




8699 62% 97.3% 
Intron-only Intron-only (i) 10172 10149  10137 99.9% 99.6% 
Neighboring-
exon 
Polymerase run (p) 
3166 1772 
 












Table A.9.  Sequencing reads, reference genome alignment and R-SAP 
characterization statistics for the ENCODE RNA-seq data for Gm12878 cell line. 
RPKM values were estimated using exon-only reads that were also classified as high-













Table A.10. New intronic-exons detected in human RefSeq transcripts (hg18) by R-
SAP from intron-only reads in MAQC Reference Human RNA-Seq dataset. 
 





Raw sequencing reads 87,929,372 
Total reference genome mapped 54,095,800 











SUPPLEMENTARY INFORMATION FOR CHAPTER 3 
 
Supplementary Methods 
RNA-Seq data pre-processing 
Forty-five breast adenocarcinoma (BRCA) primary tumors and 10 adjacent 
normal breast tissue samples were selected from ‘The Cancer Genome Atlas project’ 
(TCGA) data portal) and subsequently RNA-Seq raw data files were downloaded from 
NCBI-SRA using dbGAP. RNA-Seq data files were downloaded ‘sra’ format that were 
further converted to FastQ format files using sra-toolkit 
(http://eutils.ncbi.nih.gov/Traces/sra/?view=software).   
 
Filtering of the assembled contigs and chimer detection 
Assembled contigs were aligned to the human reference human genome (hg19 
from UCSC genome database) using 'Blast Like Alignment Tool (BLAT) (Kent 2002) 
that is a specialized program for aligning long RNA stretches to the reference genome. 
BLAT reports independent alignment of different fragments of the RNA sequences and 
allows long gaps in the alignment that can be representative of introns present in a RNA 
sequence. We observed the presence of short stretches of homopolymers (poly As and 
poly Ts) towards the ends of the assembled contigs. Such repeats may affect the overall 
alignment and may create ambiguous alignments. We, therefore, trimmed homopolymer 
repeats as well as other low complexity repeats detected using RepeatMasker 
(http://www.repeatmasker.org) and Tandem Repeat Finder 
(http://tandem.bu.edu/trf/trf.html, ). Alignment files were exported in ‘.pslx’ format from 
BLAT then were supplied to R-SAP as input for detecting chimeric transcripts. Chimeric 
transcripts result in fragmented (or split-) alignments where fragments of the chimeric 
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transcripts map to discrete genomic loci. R-SAP detects such alignments and derives the 
underlying fusion structure using the known gene models. We combined Ensembl and 
lncRNA annotations (available from UCSC genome database) in order to generate a 
comprehensive set of known gene models.  R-SAP characterized each chimeric transcript 
based upon the genic regions (5’UTR, CDS or 3’UTR) of the reference transcripts 
intersecting with the genomic loci involved in the chimeric transcript formation. 
 
Expression quantification 
We performed a two-way expression estimation on the filtered set of 1959 
chimeric transcripts. First we estimated the expression of the reference transcripts 
(comprised of Ensembl and lncRNA annotation set) that were involved in the chimer 
transcript formation. Reference transcript sequences were obtained from the UCSC 
genome database and filtered RNA-Seq reads were mapped using Bowtie. Alignment 
files were obtained in “bam” format that were sorted using Samtools (Li et al. 2009). 
Abundance was estimated as expected read counts by using RSEM ((RNA-Seq by 
Expectation Maximization) (Li and Dewey 2011). Expression values of reference 
transcripts were used to calculate the fold change of 5’- and 3’- UTR change associated 
chimers in cancer samples relative to the normal samples. Expression values were then 
normalized using “Upper quartile normalization” (Bullard et al. 2010).  
In order to determine the “pro-neoplastic” potential chimeric transcripts (see main 
text), we relied upon the expression of the chimeric transcript itself rather than the 
associated reference transcripts. We estimated the expression of shared (detected in 
normal and cancer samples) in each of the corresponding samples. RNA-Seq reads were 
mapped to the assembled contig representing the chimera and read counts were then 
estimated using RSEM. Read counts were normalized using upper-quartile normalization 
as proposed by Bullard et al. (Bullard et al. 2010). Expression fold change in cancer 
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relative to normal was computed using the average expression values measured across 
cancer and normal samples. 
 
Table B.1.  Summary statistics on raw and processed RNA-Seq data from the 55 
breast samples used in this study. Additional columns contain statistics on assembled 
contigs, initial and final number of chimeric transcripts after filtering. The first sheet in 
the excel file contains the data columns and a key describing the data is on the second 
excel sheet. 




Table B.2. Detailed alignment and annotation information on 1959 filtered chimeric 
transcripts from 55 samples analyzed in the study. Each chimeric transcript is 
represented by a unique ID in the first column. Structural and functional classification (as 
described in the text) information is presented in columns S, T and U. Cells in the gene 
name columns (‘geneName1’ and ‘geneName2’) with value “none” represent gene-desert 
regions. The first sheet in the excel file contains the data columns and a key describing 
the data is on the second excel sheet. 










Table B.3: Distribution of structural and functional classes for chimers found only 











Table B.4: Distribution of structural and functional classes for chimeras found in 
both normal and in cancer tissue samples. (A similar table for cancer specific chimers 














inter-genic gene-desert-I gene-desert-II Total 
 
fusion-protein 9 NA NA 9 
3' truncated-
protein 22 4 NA 26 
5' UTR-change 6 2 NA 8 
3'UTR-change 18 1 NA 19 
cryptic splice-site 41 6 NA 47 
novel RNA 39 6 1 46 
Total 135 19 1 155 
 
 
inter-genic gene-desert-I gene-desert-II Total 
 
fusion-protein 23 NA NA 23 
3' truncated-
protein 53 4 NA 57 
5' UTR-change 6 0 NA 6 
3'UTR-change 52 0 NA 52 
cryptic splice-site 33 15 NA 48 
novel RNA 79 4 0 83 
Total 246 23 0 269 
 139 
Table B.5: Recurrence of chimeric transcripts across cancer samples. Recurrence is 
defined as the number of samples in which a specific chimeric transcript was detected. 













Table B.6.  Cancer specific in-frame fusions where at least one protein domain from 
each (5’ and 3’) of the participating genes is covered by the ORFs involved in the 
chimera formation. Protein domain names (as defined by SMART database) are present 
in columns K and T. The first sheet in the excel file contains the data columns and a key 
describing the data is on the second excel sheet. 







Recurrence frequency percentage 
   
1 1309 93.97 
2 55 3.95 
3 17 1.22 
4 5 0.36 
5 5 0.36 
6 1 0.07 
7 0 0.00 
8 0 0.00 
9 1 0.07 
   
Total 1393 
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Table B.7. Cancer specific in-frame fusions where 3’ partner gene is up-regulated by 
> 2X relative to the intact gene in normal tissue samples. Expression is the normalized 
RNA-Seq read counts as estimated using RSEM and followed by upper quartile 
normalization. Expression fold change for the 3’- gene is present in column U. The first 
sheet in the excel file contains the data columns and a key describing the data is on the 
second excel sheet. 




Table B.8. Cancer specific chimeric transcripts with fused 5’ or 3’ UTRs and having 
the ORF of the coding gene intact and displaying > 2X change in expression relative 
to the intact gene’s expression in normal tissue. The first sheet in the excel file 
contains the key defining column entries. The second sheet contains data for chimeras 
with a fused 5’ UTR; the third sheet contains data for chimeras with a fused 3’ UTR. For 
5’-UTR fusions, the expression fold change for the 3’ partner gene is calculated; for 3’ 
UTR fusions, the expression fold change for the 5’ partner gene is calculated. The upper 
portion in each data sheet summarizes the down-regulated genes and the lower portion 
summarizes the up-regulated genes. 
 








Table B.9.  Detailed information for gene-desert-I and gene-desert-II chimeric 
transcripts. The first sheet of the excel file contains the key defining column entries. The 
data for cancer specific, normal control and shared chimeric transcripts is presented 
separately in second, third and fourth sheets, respectively.  Cells in the gene name 
columns (‘geneName1’ and ‘geneName2’) with value “none” represent gene-desert 
regions. 




Table B.10. Chimeric transcripts comprised of in-frame fusion gene transcripts 
present in both normal and cancer samples. Expression levels are presented as 
normalized RNA-Seq read counts as estimated using RSEM and upper quartile 
normalization. The first sheet of the excel file contains the key defining column entries. 
The second sheet presents the chimeric transcript annotation information. Third sheets 
presents the expression values across normal and cancer samples respectively. The 
structures of these fusion genes is presented in Figure 3.15. 
 






SUPPLEMENTARY MATERIAL FOR CHAPTER 4 
 
Supplementary Methods 
Preprocessing of the whole-genome sequence (WGS) data 
Whole genome sequencing data from TCGA was downloaded in BAM format 
that also contains metadata about the sequencing libraries. We noticed that the presence 
of multiple read-group in each BAM file. Read-groups are typically generated as a result 
of multiple sequencing runs of the, use of multiple lanes on the sequencer or difference in 
sequencing library preparation protocol for the same sample.  For each BAM file, we 




Read-groups with the similar mean insert-size and similar insert-size distributions 
were merged into single read-groups. Merging of the read-groups resulted in two read-
groups per sample. Estimated mean insert-size and standard-deviation for the insert-size 
for each group are summarized in Supplementary Table 2.  Since intra-chromosomal 
variants detection is done by considering the insert-size and standard-deviation of the 
distribution into account, downstream analysis (up to the SV (structural variant) 
breakpoint detection using de novo assembly) was done on per 'read-group basis. After 
the breakpoint detection, validated SVs from multiple read-groups were merged using the 
SV structure and breakpoint information and a non-redundant set of validated SVs was 




Inclusion of unmapped reads in the de novo assembly of SVs 
After reference genome alignment of the WGS reads, on an average there were 
300 million reads that were left unmapped. A subset of these reads may represent those 
that are spanning the breakpoints of SVs. So we included the unmapped reads in the de 
novo assembly of each SV. Since, on average, there were 19,500 SVs, it was not feasible 
to include all of the unmapped reads for the assembly of each SV. Instead, we defined a 
subset, called ‘neighborhood junction reads’, of all the unmapped reads for each SVs. 
Unmapped reads were mapped to the reference genome using the ‘local alignment’ mode 
of BowTie2 (Langmead and Salzberg 2012). Unmapped reads that were mapping 
partially within the 500 bp region around the SVs, were selected for the de novo 
assembly. 
 
Trimming of assembled contigs 
We observed the presence of simple or low-complexity repeats around the edges 
of the assembled contig resulting from the de novo assembly. Such repeats can create in 
false or ambiguous ‘split’ mapping structures during the reference genome alignment and 
can result in false SV validation calls. Also, they can increase the alignment time 
significantly since human genome is enriched with simple We, therefore, detected these 
repeats at the edges of contigs using RepeatMasker (http://www.repeatmasker.org) and 









Table C.1.  Summary statistics on processed whole genome sequencing data and 
detected structural variants from 12 samples (6 control (whole blood), 6 cancer 
patient samples). Additional columns include statistics on reference genome alignment, 
SV detections, assembled contigs and validation rate of SVs and number of RNA-Seq 
reads.  First sheet in the excel file contains the keys describing the data columns in the 
second sheet. 




Table C.2.  Table describing read-groups in the ovarian WGS data and various 
cutoffs used for the SV detection. Each sample is represented by two read-groups that 
were originally determined by TCGA following the manual merging of the similar read-
groups. Mean insert-size, standard deviation of the insert-size distribution and SVDetect 
cutoff were empirically derived using the reference genome alignment of paired-end 
WGS reads. First sheet in the excel file describes the data columns in the second sheet. 
 




























Table C.3.  Summary of the ovarian samples used to perform the microarray gene-
expression by TCGA. Each sample is represented by two read-groups that were 
originally determined by TCGA following the manual merging of the similar read-
groups. Mean insert-size, standard deviation of the insert-size distribution and SVDetect 
cutoff were empirically derived using the reference genome alignment of paired-end 




Table C.4. Detailed alignment and annotation information on 14,719 validated SVs 
from 12 ovarian samples (6 control (whole blood) and 6 ovarian cancer patient 
samples) analyzed in the study.  The table contains 4,516 somatically derived, 5,518 
germline derived and 4,685 somatic control SVs that were originally detected by 
SVDetect and later validated using de novo assembly. This table is a non-redundant table 
i.e. corrected for the multiplicity of SVs across samples and frequency across samples is 
recorded in column O, P and Q. Each SV is represented by a unique Id in the first column 
that is followed by columns with SV class, genomic coordinates and breakpoint 
information for the SV.  Columns T (‘headTx’ )to AA (‘tailGeneStrand’) contain 
information on the genes that overlap SV breakpoints were ‘NA’ indicates no overlap 
with any known gene. Last three columns define SVs characterization and functional 
classification. First sheet in the excel file contains the keys describing data columns in the 
second sheet. 
 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/dissertations/mittal.htm 
 
TCGA sample Id Tissue Tissue source Microarray chip version 
TCGA-01-0628-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0630-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0631-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0633-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0636-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0637-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0639-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-01-0642-11A ovary Solid Tissue Normal Affymetrix HT_HG-U133A 
TCGA-04-1371-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-13-0723-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-13-0725-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-13-0751-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-13-0890-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-13-1411-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-24-0982-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-24-1103-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
TCGA-25-1319-01A ovary Primary solid Tumor Affymetrix HT_HG-U133A 
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Table C.6. Distribution of somatically and germline derived SVs that were 
characterized as intra-genic SVs.  SVs were classified based on the location of 
breakpoints within the same gene. Since intra-genic SVs do not create gene-fusions, they 


















Functional class potential functional impacts 
Detectable by 
RNA-Seq? 
altered promoter Change in gene-expression No 
alternative 5'UTR Change in gene-expression Yes 
alternative 3'UTR Change in gene-expression Yes 
   
5'-truncated 
C-terminal truncated protein from the 
5'- (or head) gene, gene-expression may 
also change Yes 
coding-gene-
fusion  
(in-frame) Will encode for a fusion-protein Yes 
coding-gene-
fusion 
 (out-of-frame) will undergo NMD Yes 
uncharacterized 
RNA 
function cannot be inferred but will 
potentially form structural RNAs Yes 




derived germline derived 
   
exonic 147 140 
   
5'UTR 5 12 
3'UTR 33 31 
disruptive 40 28 
non-coding 69 69 
 
 
 intronic 2004 2740 
   
Total 2151 2880 
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Table C.7.  Somatically and germline derived inter-genic SVs that were detected by 
RNA-Seq or resulted in differential gene-expression as measured by microarray.  
The table is divided in two parts, Table 7a contains transcription detected by RNA-Seq; 
Table 7b contains SVs resulting in differential gene-expression measured by microarray. 
Each table is presented in a different excel sheet. Upper half of the sheet contains 
‘somatically derived’ SVs and lower half contains ‘germline derived’ SVs. Two 
additional sheets contain keys describing the data columns present in Table 7A and 7B. 
 




Table C.8. Detailed distribution of functional classes of inter-genic SVs among 
various structural classes of SVs.  Structural classes of SVs are ‘deletion’, ‘insertion’, 
‘inversion’, ‘inverted-duplication’, ‘tandem-duplication’, ‘translocation’ and 
‘transposition’.  Table 8A (upper half) contains data for somatically derived SVs while 
Table 8B (lower half) belongs to germline derived SVs. 
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